

**A  
N  
N  
U  
A  
L  
  
R  
E  
P  
O  
R  
T  
  
2  
0  
0  
3**



**TROPICAL DISEASE FOUNDATION**

CONTENTS	PAGE
<i>Foreword</i>	1
<i>History of the Foundation</i>	2
<i>Service Programme</i>	3
<i>Research Programme</i>	8
<i>Training Programme</i>	16
<i>Publications</i>	18
<i>Participation in Conferences</i>	23
<i>Financial Statements</i>	26
<i>Board of Trustees</i>	36
<i>Organization Chart</i>	37
<i>Benefactors</i>	39

## **FOREWORD**

*The year has been full of challenges. The Global Fund against AIDS Tuberculosis and Malaria (GFATM) approved the Philippine plan on Accelerating the Response to TB and Malaria in the Philippines. The Tropical Disease Foundation assumed an important role in this undertaking by being elected as the Principal Recipient. A significant capacity building and strengthening of partnership with public and private sector agencies involved in the programme was thus undertaken to fully respond to this awesome responsibility. In addition, important linkages with international institutions were forged to strengthen the service, research and training programmes of the TDF.*

*In addition, an important new linkage was initiated with the Tuberculosis Research Unit of the Case Western Reserve University as the third site in a clinical trial. Through this linkage, the research clinical and laboratory have been upgraded and inaugurated at the end of the year.*

*We hope to measure up to the expectations of the GFATM and our partners. At the same time, we aim to continue serving our patients as conscientiously as ever. We are grateful to the Board of Trustees of the TDF and our staff for their unstinting support and dedication.*

  
Thelma E. Tupasi, MD

## HISTORY OF THE FOUNDATION

The Tropical Disease Foundation is a private, non-stock, non-profit organization founded in 1984 by a group of physicians. It is supported by research grants, donations and endowments. Its objective is to undertake researches and provide training and service in the control and management of tropical infectious diseases.

A Memorandum of Agreement was signed with the Makati Medical Center (MMC) in 1987, and Dr. Constantino P. Manahan became the first Chairman of the Board of Trustees of the Foundation. After Dr. Manahan's untimely demise, Dr. Romeo Gustilo became Chairman of the Board of Trustees. In 2001, Dr. Raul G. Fores was elected as Chairman. From 1987 to date,

the Honorary Chairman of its International Advisory Board is Dr. Calvin M. Kunin.

Through the generosity of donors and friends, the Foundation has been able to establish its research laboratory which has gradually expanded, and now includes facilities for special microbiology, mycobacteriology, immunology, mycology, and virology. With these laboratory facilities, the Foundation has been able to pursue its activities in educational and research programs in tropical infectious diseases of public health importance. Notable among these were its community-based prospective studies on Acute Respiratory Infection (ARI) and tuberculosis.

### Linkage with the Makati Medical Center

The Makati Medical Center was founded by a group of distinguished health professionals headed by Dr. Constantino P. Manahan, who was the first Chairman of the Board and concurrent Medical Director. It is owned and operated by the Medical Doctors, Inc. and was formally inaugurated on 31 May 1969.

The Foundation complements the facilities of the MMC mainly in the fields of microbiology, immunology and virology. Subject to the rules and regulations of the MMC Institutional Review Board, the Foundation is authorized to undertake research projects in accordance with the provisions of the Helsinki Declaration. The MMC accordingly allows its staff, including

medical residents and fellows, to participate in the researches of the Foundation. In turn, the research facilities of the Foundation are also made available to the MMC personnel for the management of patients who are in need of them. The Foundation actively participates in the MMC training programs and in its other related activities.

The MMC, because of its belief in the sanctity of human life, renders equal standards of medical services to all patients regardless of their socio-economic status. Its efforts are geared toward meeting the health needs of the patients by maintaining highly qualified staff and by constantly updating its medical technology.

### Supporting the Public Sector Health Programmes

The 1997 National Tuberculosis Prevalence Survey was undertaken by the TDF on behalf of the Department of Health (DOH). For this project, the TDF was awarded the 2000 Outstanding Health Research Award. It also initiated the close collaboration between the TDF and the National TB Control Program of the Department of Health in TB Control through the initiation of the DOTS Clinic at the Makati Medical Center. This

private-public collaboration has provided free service in the management of TB patients and was the very first DOTS-Plus pilot project approved by the WHO Green Light Committee for the management of MDR-TB. As a testimony of this well established relationship with the NTP, the TDF was elected upon the nomination of the DOH as Principal Recipient of the GFATM Programmes in the Philippines.

## SERVICE PROGRAMME

### **Global Fund Against AIDS, Tuberculosis, and Malaria (GFATM): *Accelerating the Response to HIV/AIDS, Tuberculosis and Malaria.***

The purpose of the GFATM is to attract, manage, and disburse additional resources through a new public-private partnership that will make a sustainable and significant contribution to the reduction of infections, illness and death, thereby mitigating the impact caused by HIV/AIDS, tuberculosis (TB), and malaria in countries that are in need, and contributing to poverty reduction as part of the millennium development goals (MDG).

The TDF was nominated by the Department of Health as the Principal Recipient of the GFATM in the Philippines and was elected by the Country Coordinating Mechanism (CCM). The project proposals for TB and Malaria were approved by the Global Fund on the 2<sup>nd</sup> round in 2003. The Grant Agreement between the Global Fund and the TDF was signed on 11 June 2003.

The TDF upon the recommendation of the CCM chose the Philippine Rural Reconstruction Movement (PRRM) as the Sub-Recipient for Malaria. Apart from the

PRRM, implementers include the Infectious Disease Office, Malaria Control Program (MCP), Local Government Units (LGU), Kilusan Ligtas Malaria (KLM) with technical assistance from the World Health Organization.

The implementers for the TB component are the TDF at the MMC DOTS Plus for MDR TB; the National TB Control Program, Department of Health for training on TB management; the Philippine Coalition Against Tuberculosis (PHILCAT) for establishment of private-public mix Directly Observed Therapy – Short Course (PPMD) centers; and World Vision for advocacy on TB awareness with technical assistance from the World Health Organization.

The project proposal for HIV/AIDS was approved by the Global Fund on the third round. Upon approval, the CCM elected the Philippine NGO Council on Population, Health and Welfare (PNGOC) as the Sub-Recipient for HIV/AIDS.

**Table 1. Chronology of Events in the Implementation of the GF projects on Accelerating the Response to Tuberculosis and Malaria in the Philippines**


<i>Date</i>	<i>Event</i>
28-29 March 2003	GFATM Asia Partnership Development Workshop in Yangon, Myanmar
18-23 May 2003	Site visit of <i>Ms. Sandii Lwin</i> , GF Portfolio Manager
11 June 2003	Signing of Grant Agreement between the Global Fund and the TDF as the Principal Recipient of GFATM and as one of the implementers of TB
18 July 2003	Signing of Grant Agreement between the TDF and the Philippine Rural Reconstruction Movement as the Sub-Recipient for the Global Fund Malaria component
21-24 July 2003	Consultation with <i>Ms. Klara Tisocki</i> , PricewaterhouseCoopers (PwC) consultant on Procurement and Supply Management
3 September 2003	Signing of Grant Agreement between the TDF and the Philippine Coalition Against TB as one of the implementers of the Global Fund TB component
4 September 2003	Signing of Grant Agreement between the TDF and the World Vision as one of the implementers of the Global Fund TB component
4 September 2003	Visit of <i>Doris dCruz Grote</i> , GF consultant on CCM
10,21 October 2003	Evaluation of Monitoring and Evaluation Plan for TB and Malaria by <i>Dr. Erlinda Guerrero, Dr. Eumelia Salva, Dr. Jose Benito Villarama</i> , PwC consultants

**MMC DOTS Clinic: *Green Light Committee Pilot Project on DOTS-Plus for MDR-TB.***

The MMC DOTS clinic is a public-private partnership between the Makati Medical Center (MMC) and the TDF, representing the private sector, and the National TB Program of the DOH, and Barangay San Lorenzo representing the public sector. The clinic expanded into DOTS-Plus and was the very first pilot project approved globally by the Green Light Committee (GLC) of the WHO Working Group on Multi-drug Resistant

(MDR) TB. Through this approval, the TDF procures 2nd line anti-TB drugs for patients with MDR TB undergoing treatment in the clinic. Funding for this project has been through fund raising activities of the TDF, the Philippine Charity Sweepstakes Office, the Barangay San Lorenzo and the United Laboratories Inc. (figure 1) Since the approval of the GF programs in the Philippines, GFATM has become the major source of funds.

**Figure 1. Funding of the DOTS-Plus Pilot Project**




In the implementation of the DOTS-Plus at the MMC DOTS Clinic, the TDFI has fostered partnership through the Kabalikat sa Kalusugan (KsK, Partners in Health) with other local agencies including the Nutrition Center of the Philippines (NCP), the Philippine Tuberculosis Society, Inc. (PTSI), and Barangay San Lorenzo (BSL), the local government unit where the clinic is located. The Philippine Amusement and Gaming Corporation (PAGCOR) has supported the reconstruction of the Teachers Pavilion in the QI as the Tahanan ng KsK (Home for Partners in Health). This will serve as a housing facility for MDR-TB patients who live from distant areas from the treatment facility.

***Patient accrual***

As of December 2003, 180 patients with MDR-TB have already been enrolled in the DOTS-Plus program. The economic analysis of the first 105 patients showed that the DOTS-Plus program using individualized treatment regimen was found to be highly cost-effective. The GLC has now recommended that the DOTS-Plus be expanded with the end in view of making it eventually community-based and as an integral part of the NTP. Policy development based on evidence from the DOTS-Plus pilot project is currently underway with the NTP with the technical assistance of the WHO.

**Figure 2. Accrual of MDRTB patients from Feb 99 -Dec 2003**  
n=180



Private practitioners referred majorities of the patients (65%), followed by government institutions including hospitals and health centers (25%). Other referrals are from non-government institutions, friends/relatives of TB patients who had been treated at MMC DOTS, and through Contact-Transmission Study.

Only 3 of 180 patients enrolled in the five years of DOTS-Plus were new PTB cases. The remaining 177 patients were previously treated, 83 of these received only first line anti-TB drugs and 94 had received 2<sup>nd</sup> line anti-TB drugs in addition (Table 1). The 2<sup>nd</sup> line anti-TB drug usually provided was a fluoroquinolone.

**Table 1 Category of Patients on DOTS-Plus for MDR-TB**

Year	New, Never Treated	Previously Treated		Total
		Only with 1 <sup>st</sup> line anti-TB drugs	Including 2 <sup>nd</sup> line anti-TB drugs	
1999	-	3	4	7
2000	-	7	8	15
2001	2	25	56	83
2002	1	35	20	55
2003	-	14	6	20
<b>Total</b>	<b>3</b>	<b>83</b>	<b>94</b>	<b>180</b>

### *GLC Site visits*

Since its approval, five GLC site visits in the DOTS-Plus pilot project have been undertaken. The first was in 16 February 2001 by Dr. Michael Iademarco from the Centers for Disease Control (CDC), Atlanta, Georgia representing the GLC, and Drs. Dong-il Ahn and Dr. Takeshi Kasai from the WHO, WPRO, participated by Dr. Raul G. Fores, Councilwomen Milagros Hugo and Divina Abad-Santos from Barangay San Lorenzo, the TDF staff and the members of the MMC DOTS Clinic.

The 2<sup>nd</sup> site visit was done on 13 August 2001 by Dr. Dong-il Ahn and Dr. Marcus Hodge of the WHO, WPRO representing the GLC. Site visit 3 was conducted on 14 March 2002 with Dr. Michael Iademarco and Dr. Paul Arguin from the CDC, representing the GLC, and Dr. Dong-il Ahn and Dr. Marcus Hodge representing the WHO-WPRO. There were two GLC site visits in 2003; the fourth GLC site visit was in 13-17 January 2003 with Dr. Kai Vink as team leader and Myriam Henkens and Ernesto Jaramillo as members. The fifth GLC site visit was 9-12 December 2003 with Dr. Kitty Lambregts-van Weezenbeek,



Chairman of GLC and Dr. Ernesto Jaramillo representing the Secretariat with the technical assistance from Dr. Michael Voniatis, Medical Officer for TB, WHO Representative to the Philippines.

#### ***Technical inputs from other visiting experts***

Dr. Ernesto Jaramillo and Dr. Sang Jae Kim paid a courtesy call in March 2003. Dr. Young Kil Park from the Korea Institute of Tuberculosis (KIT) who assisted in the training and in the data analysis on Restricted Fragment Length Polymorphism (RFLP) 10-18 November, 2003.

Dr. Paul Jensen provided technical advice on the installation of air handling mechanisms in the renovation of the Clinic and Research Laboratory which was undertaken from July 17 to December 8, 2003 with the funding from the TBRU, Case Western Reserve University..

#### **DOTS-Plus Expansion**

The long-term goal of the DOTS-Plus program of the MMC DOTS Clinic is to establish a program of management for MDR-TB in collaboration with the NTP towards policy development on MDR-TB within the National TB Control Program of the DOH. The cohort expansion to include 750 more patients in DOTS-Plus will require

quality assurance of the TDF laboratory by a supranational laboratory and assurance that all doses be administered under directly observed treatment (DOT).

The GLC recommends a strong collaboration between the NTP and MMC DOTS-Plus particularly for DOT which can be undertaken by the public health centers under NTP in keeping with the WHO headquarters recommendation that DOTS-Plus should be mainstreamed with DOTS. It is not possible for MMC-DOTS Plus center to serve the needs of the Philippines.

Two of the 2<sup>nd</sup> line drugs are readily available in the Philippine market and are widely used by private physicians as well as the DOTS Clinic of the Lung Center where cure rates of 11-22% were observed. This increases the chance of incorrect use of 2<sup>nd</sup> line anti-TB drugs and the inadequate treatment of patients, thus amplifying the drug resistance of M. tb. The GLC recommends for the Philippines to address this issue

The involvement of the Lung Center in the DOTS-Plus pilot project on condition that they are able to meet the criteria set by GLC may be considered. Designing regimen through a concillium like what is done in other countries may be undertaken and DOT can be performed in the Lung Center under the supervision of the MMC DOTS-Plus pilot project.

## Research Programme

Research projects are done in collaboration with local and foreign institutions and universities. The research programme helps to establish linkages in order to facilitate technology transfers. Since 1987,

research projects have been conducted on a variety of infectious disease problems. Most of the research activities undertaken are related to the service program at the DOTS Clinic.

### *Current Research Projects:*

1. DMID Protocol Number 01-009 Version 1.3: *Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy from 6 Months to 4 Months in HIV-non-infected Patients with Fully Drug Susceptible, Non-cavitary Pulmonary Tuberculosis with Negative Sputum Cultures after 2 months of anti-TB treatment.*

The TDF was included as the third site for the international multicenter clinical trial in collaboration with Case Western Reserve University Tuberculosis Research Unit (TBRU) last 17 November 2003. Other sites are Makerere Medical School, Mulago

Hospital and Complex, Uganda which started the project on 2 April 2002) and –NDI, Nucleo de Doencas Infecciosas, Universidade Federal de Espirito Santo, Vitoria, ES Brazil on 26 December 2002.

**Table 2. Chronology of Events in the Initiation of Collaboration with the TB Research Unit, Case Western Reserve University**

<i>Date</i>	<i>Event</i>
November 2002	Site Visit by <i>Dr. Henry Boom</i> , Director, TBRU, CWRU
1-7 April 2003	Site visit by <i>Dr. John Johnson</i> and <i>Dr. Kathleen Eisenach</i> , TBRU, CWRU
21 January 2004	Approval by the National Institute of Allergy and Infectious Disease (NIAID) National Institutes of Health (NIH) USA, of the TDF as the third site for the Treatment Shortening Study of the TB Research Unit (TBRU), Case Western Reserve University(CWRU)
16-20 February 2004	Workshop on the Fundamentals of International Clinical Research, Bangkok, Thailand attended by <i>Ma. Imelda D. Quelapio, MD</i> , <i>Ruth Orillaza, MD</i> , <i>Nona Rachel Mira, RN</i>
29 September – 3 October 2003	Site Initiation Visit by <i>Julia Welch</i> , Family Health International, Research Triangle, Ann Harbor, Michigan
17-20 November 2003	Orientation Visit on Data Management by <i>Dana Jankus</i>

2. Eli Lilly (Phils) Inc.: *Promoting Global Research Excellence in Severe Sepsis (PROGRESS) An International Observational Study among Severe Sepsis Patients Treated in the Intensive Care Unit.*

This descriptive study is undertaken by the Infectious Disease Fellows. To date, a total of 54 of 120 patients have been enrolled in the study. Data are being submitted and encoded at the central coordinating unit of the sponsor, Eli Lilly Co.

3. Pfizer, Inc.: *Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections*

This is a multicenter clinical trial IND No. 49195 to evaluate the efficacy of Linezolid as treatment for intravenous catheter related infections and started in the Philippines 22 August 2002. As of June 2004, 8 patients have been enrolled from our center.

4. United Laboratories Inc.: *A Double-Blind Randomized Controlled Trial Comparing the Efficacy and Safety of the Commercially Available Mupirocin 2% Ointment and Mupirocin 2% Ointment – Unilab Formulation in the Treatment of*

*Superficial Bacterial Skin Infection – A registration Trial.*

The TDF provides laboratory support for this registration trial which is being undertaken by Dr. Roberta C. Romero as principal investigator, assisted by the residents of the Department of Dermatology, Makati Medical Center. The study was started 10 March 2004.

5. Bristol Myers Squibb: *SENTRY*

This is a continuing project which is a multi-country collaborative project in Asia Pacific with sites in Australia, China, Japan, Korea, Singapore, South Africa, Taiwan ROC under the leadership of Dr. John Turnidge and Ms. Jan Bell at Women's and Children's Hospital, Adelaide, Australia. The objectives of this study are to 1) determine the frequency of occurrence of pathogens causing blood stream infections (BSI) and wound and urinary tract infections in hospitalized patients, and 2) assess the antimicrobial resistance patterns of these isolates including yeast as well as that of fastidious organisms causing upper and lower respiratory tract infections, and gastroenteritis pathogens isolated from stool and blood cultures, and pathogens among infected paediatric patients.

**Table 3. Research and Service Projects and Funding Agencies**

Research Projects (Year Undertaken)	Sponsor
Accelerating the Response to TB and Malaria in the Philippines (2003)	<i>Global Fund to Fight AIDS, TB and Malaria</i>
A Double Blind Randomized Controlled Trial Comparing the Efficacy and Safety of the Commercially Available Mupirocin 2% Ointment and Mupirocin 2% Ointment – Unilab Formulation in the Treatment of Superficial Bacterial Skin Infection – A registration Trial.	<i>United Laboratories Inc</i>
Promoting Global Research Excellence in Severe Sepsis (PROGRESS) An International Observational Study among Severe Sepsis Patients Treated in the Intensive Care Unit.	<i>Eli Lilly</i>
Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy from 6 Months to 4 Months in HIV-non-infected Patients with Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis with Negative Sputum Cultures after 2 Months of Anti-TB Treatment (2003)	<i>National Institute for Allergy and Infectious Disease National Institutes of Health US Department of Health and Welfare</i>
Economic Analysis of the DOTS-Plus for Multi-Drug Resistant Tuberculosis (MDR-TB) in the Philippines (2003)	<i>Stop TB, TB Strategy and Operations World Health Organization</i>
Promoting Global Research Excellence in Severe Sepsis (PROGRESS) (2003)	<i>Eli-Lilly</i>
Phase I International Clinical, Operational, Health Service Training Award in HIV/AIDS and Tuberculosis (2002-3)	<i>Fogarty Institute National Institutes of Health US Department of Health and Welfare</i>
Research Capability Strengthening Grant: MMC DOTS-Plus (2002)	<i>World Health Organization –TDR</i>
Multi-Centre IND Study on Linezolid vs Vancomycin/Oxacillin/Dicoloxacillin in Catheter related Bacteremia (2002)	<i>Pfizer (USA)</i>
Management of Adverse Drug Reactions in DOTS-Plus (2002)	<i>Stop TB Strategy and Operations Unit (TBS)</i>
A randomized, open label, comparative, multi-centre IND Study on Voriconazole in Candidemia of non-neutropenic subjects.	<i>Pfizer (USA)</i>
Contact Tracing among Household Contacts of Multidrug-Resistant TB Cases (2001)	<i>Mayo Clinic, Rochester, Minnesota</i>
MMC DOTS-Plus Pilot Project (2001)	<i>Philippine Charity Sweepstakes Office</i>
SENTRY (March-December 2000)	<i>Bristol-Myers Squibb</i>
Gram-positive Bacteremia at the Makati Medical Center (January 1999-March 2000)	<i>Pharmacia Upjohn</i>
SENTRY (March-December 1999)	<i>Bristol-Myers Squibb</i>
A Double-Blind Study Comparing the Safety and Efficacy of Cefepime versus Ceftazidime in Severe Bacterial Infections (March-December 1999)	<i>Bristol-Myers Squibb</i>

Point-in-Time Determination of the Antimicrobial Activity of Cefepime Compared to Other Broad-Spectrum Beta-Lactams at Medical Centers in the Philippines (February-December 1998)	<i>Bristol-Myers Squibb</i>
The Efficacy of Sublingually Administered Natural Human Interferon Alpha in the Treatment of Patients with Chronic Active Hepatitis B (1992-1998)	<i>Pharma Pacific Management Pty Ltd., Australia</i>
The Second Nationwide Tuberculosis Prevalence Survey (March-December 1997)	<i>World Bank and the Philippine Health Development Project (PHDP)</i>
Prevalence Survey of the Dermatologic Diseases in the Philippines (April-June 1997)	<i>Janssen Pharmaceuticals</i>
Seroepidemiologic Study of Hantaviruses in the Philippines (April-June 1997)	<i>Glaxo-Wellcome Philippines Vizcarra Pharma</i>
Tuberculin Skin Testing among Healthcare workers at the Makati Medical Center (1996-1997)	<i>Glaxo-Wellcome Philippines</i>
Comparison Between 7H9 with OADC Enrichment Broth and Solid Lowenstein Jensen Medium for Primary Isolation of Mycobacteria (1995-1996)	<i>Astra Fund for Clinical Research and Continuing Medical Education (AFCRCME)</i>
Multi-center Study on Lincomycin for Streptococcal Pharyngitis (1995-1996)	<i>Upjohn Philippines</i>
Multi-center Study on Short-Course 2% Clindamycin Vaginal Cream vs. Oral Metronidazole for Bacterial Vaginosis (1996)	<i>Upjohn Philippines</i>
In-vitro Study of Pefloxacin vs. Ciprofloxacin and Ofloxacin (1996)	<i>Rhone-Poulenc Rorer</i>
Spectrum of Ulcerative Keratitis at the Makati Medical Center (1993)	<i>Glaxo-Philippines, Inc.</i>
In-vitro Susceptibility of Gram-negative and Gram-positive Pathogens to Tosufloxacin as Compared with Other Quinolones (1992-1993)	<i>Cyanamid Lederle (Phils), Inc.</i>
In-vitro Susceptibility of Bacterial Isolates to Cefepime as Compared to Ceftazidime and Ceftriaxone (1992)	<i>E.R. Squibb and Sons</i>
A Randomized Open-label, Comparative Multi-center, Study of Parenteral Piperacillin/Tazobactam Versus Ceftazidime Plus Metronidazole in the Treatment of Hospitalized Patients with Intraabdominal Infections (1991-1992)	<i>Cyanamid Lederle (Phils), Inc.</i>
Piperacillin and Tazobactam Sensitivity Profile (1991-1992)	<i>Cyanamid Lederle (Phils), Inc.</i>
Short-term Chemotherapy of Leprosy with Minocycline and Rifampicin (1991)	<i>Cyanamid Lederle (Phils), Inc.</i>
Minocycline in the Treatment of Lepromatous Leprosy (1990)	<i>National Research Council of the Philippines</i>
Lymphoblastoid Interferon Alpha in the Management of Chronic	<i>Wellcome Foundation Ltd.</i>

---

Hepatitis B Infection (1989-1990)	
Levels of Prostacyclin and Thromboxane in Pregnancy-Induced Hypertension (1989-1990)	<i>International Development Research Centre</i>
Traditional Practices and Ritual Therapy on Acute Respiratory Infection (1989-1990)	<i>National Research Council of the Philippines</i>
Inhibitory and Sensitivity Patterns of Local Common Pathogens to Aztreonam (1989)	<i>E.R. Squibb &amp; Sons</i>
Multi-drug Therapy in Leprosy (1988-1990)	<i>Cyanamid Lederle (Phils), Inc</i>
Surveillance of Ofloxacin Resistance (1987-1990)	<i>Daiichi</i>
Acute Respiratory Infection in Childhood: Data Analysis (1987-1990)	<i>Board on Science and Technology for International Development, U.S. National Academy of Sciences</i>
Etiology of Childhood Acute Respiratory Infections: Pathophysiologic Studies (1991)	<i>Board on Science and Technology for International Development, U.S. National Academy of Sciences</i>
Acute Respiratory Infection (1987)	<i>Astra Pharmaceuticals (Phils), Inc.</i>
Chlamydia Infection in Filipino Women(1987)	<i>U.S. Naval Medical Research Unit 2 (NAMRU)</i>

---

## TRAINING PROGRAMME

By the very nature of its work, the Foundation is in constant need of personnel trained in special laboratory techniques. The Foundation therefore makes it possible to have its staff trained in different hospitals and laboratories here and abroad. Table 9 shows the grantees, sponsors and institutions where they trained.

### *Fellowship Program in Infectious Disease:*

Post residency training residents from internal medicine or pediatrics have been admitted into the two year training program, with an optional third year. For the year 2002-2004, Dr. Ma. Tarcila Gler and Dr. Gamaliel Garcia have been training fellows in infectious diseases. They will bring up the total of trained fellows in the program to 13.

**Table 4. Graduates of the Fellowship Program**

<i>Fellows</i>	<i>Years</i>
Marivyl Javato	1987-88
Rebecca Littaua	1987-88
Maria Lourdes Gomez-Gozali	1988-89
Mamerto G. Garvez	1989-90
Vilma M. Co	1991-92
Ellamae M. Sorongon-Divinagracia	1993-94
Evelyn Alesna	1995-97
Maria Imelda.D. Quelapio	1996-98
Maria Lourdes A. Villa	1997-99
Carmela A. Rivera	1998-2000
Faith D. Villanueva	1999-2001

### *Exchange Fellowship Training in Collaboration with Mayo Clinic*

The TDF has entered into a memorandum of understanding to initiate an exchange fellowship training in infectious disease. Through this MOU, fellows in infectious diseases from the TDF/MMC will rotate for four weeks at the Mayo clinic and in return, fellows from the Mayo Clinic will rotate for four weeks at the MMC.

### *Training on DOTS and DOTS-Plus for the Management of TB*

The TDF obtained the PhilCAT accreditation for PhilHealth outpatient TB Package in July 24, 2003. This allowed the TDF to undertake a training program on Basic Course on DOTS on November 28, 2003 for 80 trainees. In addition, six training courses on DOTS-Plus implementation for health workers and community

volunteers from Metro Manila and nearby provinces have been undertaken.

**Table 5. Training on DOTS and DOTS Plus conducted by the DOTS staff.**

<i>Date</i>	<i>Venue</i>	<i>Type of Training</i>	<i>Participants</i>
28 Nov. 2003	Makati Medical Center Makati City	Basic Course on DOTS	<b>80</b> Private Physicians and resident medical doctors
9 Oct. 2003	St. Claire Patronage of the Sick Poor Community Center Pandacan, Manila	Training on DOTS Plus	<b>20</b> Community health volunteers from Pandacan and Sta. Ana, Manila, and Cavite
14 Nov. 2003	Don Bosco Parish Church Makati City	Training for Community Treatment Partners	<b>25</b> Volunteers from faith-based organizations; barangay health workers from Pasay, Manila and Makati; health volunteers from the Committee of German Doctors; residents from Urban Botanical Garden (urban poor area)
4 Dec. 2003	TDF, Medical Plaza Makati Makati City	Training on DOTS Plus	<b>4</b> Public health center workers from Manila Health Department
16 Dec. 2003	Makati City Health Department, Makati City Hall	Training on DOTS Plus	<b>37</b> Public health workers in Makati
17 Dec. 2003	Makati City Health Department, Makati City Hall	Training on DOTS Plus	<b>30</b> Doctors from Barangay health centers and Makati Main office, public health nurses and midwife

***CDC Implemented Training on Preventing the Institutional Transmission of Tuberculosis and Multidrug-Resistant Tuberculosis***

At the request of the TDF, and with funding from the U.S. Agency for International Development (USAID), the Division of Tuberculosis Elimination (DTBE), National Center for HIV, STD and TB Prevention (NCHSTP) at the Centers for Disease Control and Prevention (CDC) conducted a two and a half day training course on Preventing the Institutional Transmission of Tuberculosis (TB) and Multidrug-Resistant (MDR) TB in the Philippines. The course was held in MMC from August 26-28, 2003 attended by a total of 80 participants, including representatives from MMC, Ospital ng Makati (OSMAK), the Research Institute for Tropical Medicine (RITM), the Philippines Hospital Infection Control Society (PHICS), and the Quezon Institute (QI)



## **Intramural Training Program**

Staff of the TDF who have undergone training in 2003 are shown in Table 3. All staff members underwent a training course conducted by the Pfizer Foundation on Good Clinical Practice in preparation for the Clinical Trial on the TB Treatment Shortening Study in collaboration with the TBRU of Case Western Reserve University which was followed up by another workshop on Statistical Package.

Mr. Virgil Belen, public health

## **Infection Control**

The Infection Control Committee (ICC) of the Makati Medical Center was created to establish the standard operating patient care program for the prevention, investigation, surveillance and control of nosocomial infections. The ICC is a hospital committee responsible to the medical staff. The working committee includes staff members from the section of Infectious Diseases and representatives from the departments of Microbiology and Pathology, Pharmacy, Dietary and Housekeeping Services, Medicine, Surgery, Obstetrics, Pediatrics, Emergency Room and the Hospital

## **Guidelines on Antimicrobial Therapy**

This manual is a biennial project of the foundation intended to provide physicians with a handy reference on empiric antimicrobial therapy. This is part of the foundation's contribution to the fellowship training program, as fellows take active part in the project by providing evidence-based data to update antimicrobial information and recommendations. The first edition published in 1988 was followed by subsequent editions in 1990, 1993, 1996, 1998 and the 6<sup>th</sup> edition in 2000. The latest edition is due for publication in 2004.

nurse at the MMC DOTS clinic underwent training on the NTP-DOTS for DOTS implementers and subsequently a follow-up training on Competency-based training and needs analysis. Ms. Noemi Ann Casinillo, a laboratory staff of the TDF research laboratory underwent bench training at the Korea Institute of Tuberculosis on Training Course for Laboratory Service in Tuberculosis Control (smear microscopy, culture drug susceptibility testing and molecular technique)

Administration. The committee holds regular monthly meetings to formulate policies for the control of infections, review various surveillance programs and employees' health program, and constantly assesses the effectivity and implementation of ICC policies and guidelines.

With the outbreak of the Severe Acute Respiratory Syndrome (SARS) in April 2003, the Infection Control Committee conducted teaching programs with the Medical and Paramedical Staff on infection control measures to be instituted to prevent nosocomial transmission in the event of an admission of a patient with SARS.

## **Rational Antimicrobial Usage**

This is a continuing project of the Infection Control Committee aimed at preventing the emergence of bacterial resistance to antibiotics by means of continuous surveillance of the susceptibility patterns of common hospital bacterial pathogens.

Results of the surveillance are reported quarterly in a hospital paper, the MMC Observer, and serve as the basis for the quarterly recommendations of antimicrobial usage.

**Table 6. Training Grants since 1987**

Name	Training Grant (Sponsor)	Venue
TDF Staff 3-4 November 2003	Workshop on Statistical Package (TDF)	Medical Plaza Makati
TDF Staff 26-28 August 2003	Infection Control Workshop (Centers for Disease Control)	Makati Medical Center
TDF Staff 26-27 June 2003	Good Clinic Practice (Pfizer, TDF)	New World Hotel, Makati City
Virgil A. Belen 14-16 May 2003	Training on NTP-DOTS for DOTS Implementors (TDF, DOH, PHILCAT, GlaxoSmithkine)	GlaxoSmithkline Building, Makati City
Virgil A. Belen 10 April 2003	Competency Based Training and Needs Analysis	Makati Medical Center
Noemi Ann Casinillo, RMT 11 March – 18 June 2003	Training Course for Laboratory Service in Tuberculosis Control (smear microscopy, culture drug susceptibility testing and molecular technique)	Korean Institute of Tuberculosis (KIT), Seoul, Korea
Ma. Imelda D. Quelapio, MD Thelma E. Tupasi, MD November 13-15, 2002	Training on DOTS-Plus WHO STOP TB Unit	World Health Organization, Geneva Switzerland
Ruth B. Orillaza, MD Virgil Belen, BSN 10 June-5 July 2002	Multidrug-resistant TB Treatment and Management through DOTS-Plus (CDC, Atlanta, Georgia)	Riga, Latvia
Nellie V. Mangubat, BSFT Michael Arabit, BSPH June 24-28, 2002	Drug Procurement for Tuberculosis Management Sciences for Health (MSH) /Program for Appropriate Technology in Health (PATH), WHO STOP TB	Jakarta, Indonesia
Ephraim Grimaldo, RMT Oct. 21- Dec. 15, 2001	Restricted Fragment Length Polymorphism (RFLP) (RCS/UNDP/TDR WHO)	Korean Institute of Tuberculosis (KIT), Seoul, Korea
Thelma E. Tupasi, MD Nona Rachel Mira, RN Nov. 1, 2001	TB Health Economics	32 <sup>nd</sup> IUATLD Conference, Paris, France
Alicia Rivera, RMT Aug. 4-Oct. 15, 2001	Molecular Biology (Glaxo-SmithKilne)	Institute of Tropical Medicine, Antwerp, Belgium
Faith D. Villanueva, M.D. Jerose O. Derilo, RMT March 15-19, 2000	Basic Course on Medical Mycology	Philippine Columbian Association Clubhouse, Manila, Philippines
Ma. Socorro M. Clarin, RMT Rowena C. Cardaño, RMT March 11-16, 2000	CMV pp65 Antigenemia Assay	Queen Mary Hospital Pokfulam Road, Hong Kong
Ma. Lourdes A. Villa, M.D. Rowena C. Cardaño, RMT April 9-21, 1999	Basic Course on Medical Mycology (Pfizer)	University of Santo Tomas Manila, Philippines
Evelyn T. Alesna, M.D. Sept 1996-July 1997	Group Training Course on Advanced Microbial Diseases Study (JICA)	Research Institute for Microbial Diseases (Biken), Osaka University in Osaka, Japan
Alicia B. Rivera, RMT 21-28 September 1997	Drug Susceptibility of Mycobacteria (Rhône-Poulenc Rorer)	Korean Institute of Tuberculosis (KIT), Seoul, Korea
Zenaida A. Chua, R.N. Feb 18-23, 1996	Hospital Infection: Enhancing Present Arrangements	London

Ma. Imelda D. Quelapio, M.D. 1996	Basic Course on Medical Mycology (Pfizer)	University of Santo Tomas Manila, Philippines
Evelyn T. Alesna, M.D. 1995	Basic Course on Medical Mycology (Pfizer)	University of Santo Tomas Manila, Philippines
Jocelyn M. Lazo, RMT May – July 1994	Detection of M. tuberculosis by Polymerase Chain Reaction (Daiichi)	Nagasaki University Japan
Vilma M. Co, M.D. November, 1994	Nosocomial Infectious Diseases and Hospital Epidemiology (Makati Medical Center)	Harvard Medical School Children's Hospital, Boston, Massachusetts U.S.A.
Alicia B. Rivera, RMT 13 April - 2 July 1993	Antifungal Assays (British Medical Council)	Regional Dept. of Infectious Diseases and Tropical Medicine Univ. of Manchester, U.K. University of Leeds, U.K.
19-23 April 1993	BSM Course in Diagnostic Medical Mycology (British Medical Council)	
Benilda Q. Baello, RMT 17-28 May 1993	Respiratory Infections in Immunocompromised Patients (Insular Life Assurance Co., Ltd)	National Institutes of Health, Bethesda, Maryland, U.S.A.
Melanie B. Nogoy, RMT September 1991-March 1992	Basic Training on Electron Microscopy (Insular Life Assurance Co., Ltd)	National University of Singapore
Normando C. Gonzaga, M.D. 28 October-1 November 1991	WHO Bi-regional Training Course on Electron Microscopy in Biomedical Research and Diagnosis of Human Diseases (WHO)	Chulalongkorn University Bangkok, Thailand
Normando C. Gonzaga, M.D. October – November 1990	Immuno-electron Microscopy And Gold Immunoblotting In Chronic Hepatitis B Infection (Wellcome)	National University of Singapore
Lerma C. Baes, RMT 1990	Rapid Viral Diagnosis, Chlamydia Isolation (Daiichi)	National Institute of Health Mahidol University Bangkok, Thailand
Normando C. Gonzaga, M.D. October – November 1990	Immuno-electron Microscopy And Gold Immunoblotting In Chronic Hepatitis B Infection (Wellcome)	National University of Singapore
Lerma C. Baes, RMT 1990	Rapid Viral Diagnosis, Chlamydia Isolation (Daiichi)	National Institute of Health Mahidol University Bangkok, Thailand
Marivyl Javato-Laxer, M.D. Eileen E. Navarro, M.D. 1988-1989	Immune Mechanism of Schistosoma japonicum (NAMRU)	George Washington Univ. Medical Center Washington, D.C., U.S.A.
Eileen E. Navarro, M.D. Lolita Tolentino, RMT 1988	Clinical Features of Viral and Bacterial Infections, Immunologic Monitoring & Rapid Diagnostic Techniques in Transplant Patients (Mr. Freddie Elizalde)	Children's Hospital of Pittsburgh, U.S.A.
Lolita Tolentino, RMT 1988	Antibiotic Susceptibility Testing by MIC, Mycobacteriology	Nagasaki University Nagasaki, Japan
	Identification of P. carinii & L. pneumophila; Viral Antigen Detection from Clinical Specimens (Daiichi, Boie-Takeda, and Filipino-Chinese Medical Specialty Scholarship Foundations)	Sendai National Hospital Japan
Thelma E. Tupasi, M.D. 1988	Influenza and Respiratory Syncytial Virus (WHO)	National University of Singapore
Ma. Lourdes O. Gomez, M.D. 1988	Oral Rehydration for Diarrhea (Tropical Disease Foundation)	San Lázaro Hospital Philippines
Thelma E. Tupasi, M.D. Nellie V. Mangubat, BSFT 1987	Computerized Data Management (National Academy of Sciences, Board on Science and Technology for International Development)	University of Maryland College Park, Maryland, U.S.A.

## Publications

2003

### Transmission of multidrug resistant *M. tuberculosis* to Filipino household contacts

Sia IG, Tupasi TE, Wengenack NL, Quelapio MID, Hall L, Orillaza R, St. Sauver JL, Luchavez E, Roberts GD, Jerpersen DJ, Grimaldo E. *Abstract*

### Tuberculosis infection and disease in children living in households of Filipino patients with TB treated at the MMC DOTS Clinic: a preliminary report.

Salazar-Vergara RN, Sia IG, Tupasi TE, Alcaneses MR, Quelapio MID, Orillaza RB, Co VM, Beltran G, Legaspi JD, Rostrata PZ, Tecson EB, Corpuz LB. *Int J Tuberc Lung Dis*. 2003; 7(Supplement 3): S494-S500.

### DOTS-Plus for MDR-TB in the Philippines: Global assistance urgently needed.

Tupasi TE, Quelapio MID, Orillaza RB, Alcantara C, Mira NR, Abeleda MR, Belen VA, Arnisto NM, Rivera AB, Grimaldo ER, Derilo JO, Dimarucut W, Arabit M, Urboda D. *Tuberculosis (Edinb)* 2003; 83(1-3):52-8.

2002

### DOTS-Plus in the Philippines, a high burden country: funds needed.

Tupasi T. Round table discussion of Pablos-Mendez A, Gowda DL, Friedem TR. Controlling MDR-TB and access to expensive drugs: a rational framework. *Bulletins of the World Health Organization* 2002; 80(6):497.

2001

### Increased Resistance to Ciprofloxacin and Ofloxacin in Multidrug-Resistant *Mycobacterium tuberculosis* Isolates from Patients Seen at a Tertiary Hospital in the Philippines.

Grimaldo ER, Tupasi TE, Rivera AB, Quelapio MIC, Cardaño RC, Derilo JO, Belen VA. *Int J Tuberc Lung Dis* 5 (6): 546-550.

2000

### Have Ciprofloxacin and Ofloxacin Lost Their Efficacy Against Multi-Drug Resistant Tuberculosis?

Grimaldo ER, Rivera AB, Cardaño RC, Derilo JO, Belen VA, Tupasi TE. 7<sup>th</sup> Western Pacific Congress of Chemotherapy and Infectious Diseases, 11-14 December 2000, Hong Kong Convention Center, Hong Kong (abstract)

### Are Standard Regimens for Tuberculosis Prudent in Settings with High Drug Resistance?

Quelapio MID, Mira NRC, Abeleda MR, Rivera AB, Tupasi TE, Grimaldo ER, Mangubat NV, Belen VA, Derilo JO. 7<sup>th</sup> Western Pacific Congress of Chemotherapy and Infectious Diseases, 11-14 December 2000, Hong Kong Convention Center, Hong Kong (abstract)

### Prevalence of *Mycobacteria* other than *Tuberculosis* in the Philippines

Rivera AB, Tupasi TE, Balagtas ED, Cardaño RC, Baello BQ, Quelapio MID, Villa MLA, Pascual MLG, Co VM, Mantala MJ. 7<sup>th</sup> Western Pacific Congress of Chemotherapy and Infectious Diseases, 11-14

December 2000, Hong Kong Convention Center, Hong Kong (abstract)

### Guidelines on Antimicrobial Therapy, 6<sup>th</sup> edition, 2000-2001

Tupasi TE, Limson BM, Romero RC, Co VM, Romulo RLC, Gozali MLG, Cayco MT, Abiad, HG, Quelapio MID, Villanueva FD, Villa MLA, Rivera CA. Limlingan ET

### Tuberculosis in the Urban Poor Settlements in the Philippines

Tupasi TE, Sistia R, Quelapio, MID, Pascual, ML, Rivera AB, Sarmiento A, Co VM, Sarol JN, Beltran G, Legaspi JD, Mangubat NV, Reyes AC, Solon M, Solon FS, Burton L, Mantala MJ  
*Int J Tuberc Lung Dis* 2000;4(1),4-11

### BCG Coverage and the Annual Risk of Tuberculosis Infection Over a 14-Year Period in the Philippines Assessed from Nationwide Prevalence Surveys

Tupasi TE, Radhakrishna S, Pascual ML, Quelapio MID, Villa MLA, Sarol JN, Co VM, Mangubat NV, Reyes AC, Sarmiento A, Solon M and Solon F  
*Int J Tuberc Lung Dis* 2000;4(3):216-222

### Seroepidemiology of Hantavirus in the Philippines

Quelapio MID, Villa MLA, Clarin MS, Bacosa M, Tupasi TE  
*International J of Infect Dis* 2000;4:104-107

### Multi-Drug Resistant Tuberculosis: Implications for Therapy

Rivera AB, Tupasi TE, Balagtas ED, Cardaño RC, Baello BQ, Quelapio MID, Villa MLA, Pascual ML, Co VM, Mantala MJ  
*Phil J Microbiol & Inf Dis* 2000;29(2):68-72

### Bacillary Tuberculosis in Rural and Urban Communities in the Philippines

Tupasi TE, Rivera AB, Villa MLA, Quelapio MID, Co VM, Balagtas ED, Cardaño RC, Mangubat NV, Pascual ML, Baello BQ  
*Phil J Microbiol & Inf Dis* 2000; 29(2):73-79

### Directly Observed Therapy-Short Course (DOTS) at the Makati Medical Center

Quelapio MID, Mira NRC, Abeleda MR, Rivera AB, Tupasi TE, Grimaldo ER, Mangubat NV, Belen VA, Derilo JO  
*Phil J Microbiol & Inf Dis* 2000;29(2):80-86

### The Power of Knowledge to Effect Change: the 1997 Philippines nationwide tuberculosis prevalence survey.

Tupasi T.  
*Int J Tuberc Lung Dis* 2000;4(10):990

### Bacillary Disease and Health Seeking Behavior among Filipinos with Symptoms of Tuberculosis: Implications for Control

Tupasi TE, Sista R, Co VM, Villa MLA, Quelapio MID, Mangubat NV, Sarol JN, Rivera AB, Pascual ML, Reyes AC, Sarmiento A, Solon M, Solon FS, Burton L, Mantala MJ  
*Int J Tuberc Lung Dis* 2000;4(12):1126-1132.

### 1999

#### **The 1997 Nationwide Tuberculosis Prevalence Survey in the Philippines**

Tupasi TE, Radhakrishna S, Rivera AB, Pascual MLG, Quelapio MID, Co, VM, Villa MLA, Beltran G, Legaspi JD, Mangubat NV, Sarol JN, Reyes AC, Sarmiento A, Solon M and FS, and Mantala MJ.  
*Int J Tuberc Lung Dis* 3(6):471-477

#### **Drug-Resistant TB in the Philippines**

Rivera AB, Tupasi TE, Balagtas ED, Cardaño RC, Baello BQ, Quelapio MID, Villa MLA, Pascual MLG, Co VM, Mantala MJ  
*Int J Tuberc Lung Dis* 3(7):639-641

#### **Quinolone use in the developing world: state of the art.**

Tupasi TE.  
*Drugs* 1999; 58 Suppl 2:55-9.

#### **Current clinical practice in the management of community acquired pneumonia: an appraisal.**

Villa MLA, Sumagaysay I, We M, Co V, Mendoza M, Tupasi TE.  
*Phil J Microbiol & Inf Dis* 199;28(4):121-127.

### 1998

#### **Guidelines on Antimicrobial Therapy, 5<sup>th</sup> edition, 1998-1999**

Tupasi TE, Limson BM, Romero RC, Co VM, Gozali LG, Lecciones JA, Alesna ET, Quelapio MID, Villa MLA and Rivera CA

### 1997

#### **Rapid and Improved Recovery Rate of *Mycobacterium tuberculosis* in Mycobacteria Growth Indicator Tube combined with Solid Lowenstein Jensen Medium**

Rivera AB, Tupasi TE, Grimaldo ER, Cardano RC, and Co VM.  
*International Journal of Tuberculosis and Lung Disease* 1997;1(5):454-459

#### **Antibiotic Usage in Community-Acquired Pneumonia in a Tertiary Care Hospital**

Magalit PN, Sorongon ED, and Tupasi TE. *The Philippine Journal of Microbiology and Infectious Diseases* April-June 1997;26(2):109-112

#### **Sublingual Interferon Alpha in the Treatment of Chronic Hepatitis B: Its Clinical, Biochemical and Biologic Effects**

Co VM, Clarin SM, Mangubat NM, Lazo J, Alesna ET, Gonzaga NC and Tupasi TE. *The Philippine Journal of Microbiology and Infectious Diseases* April-June 1997;26(2): S53-S60

#### **Morphologic Liver Changes in Hepatitis B: Impact of Interferon**

Gonzaga NC, Garvez MD, Nogoy M, Abrabtes F, Ng M, Tupasi TE

*The Philippine Journal of Microbiology and Infectious Diseases* April-June 1997;26(2):S61-S66

### 1996

#### **Guidelines on Antimicrobial Therapy, 4<sup>th</sup> edition, 1996**

Tupasi TE, Limson BM, Romero RC, Co VM, Lecciones JA, Gozali LG, Sorongon ED, Alesna ET

#### **Pharmacodynamics as Basis for Rational Antimicrobial Dosing**

Tupasi TE  
*The Philippine Journal of Microbiology and Infectious Diseases* 1996 Dec;25(2):70-77

#### **Multiple Sexual partners: Risk Factor for Bacterial Vaginosis.**

Alesna E, Pascual-Viduya M, Rivilla-Manalastas MA, Baello B, Cardano RC, Borromeo R, Tupasi TE  
*The Philippine Journal of Microbiology and Infectious Diseases* 1996 June;25(1):1-3

#### **Antibiotic Use in the Western Pacific: Viewpoint from the Philippines**

Tupasi TE  
*Proceedings; 5<sup>th</sup> Western Pacific Congress of Chemotherapy and Infectious Diseases* 1996; 154-160

#### **Life-threatening Group A Streptococcal Infections**

Tupasi TE. *The Philippine Journal of Microbiology and Infectious Diseases* 1996 June;25(1):21-25

### 1995

**Aflatoxin and Outcome from Acute Lower Respiratory Infection in Children in the Philippines.** Denning DW, Quiapo SC, Altman DG, Makarananda K, Neal GE, Camallere EL, Morgan MRA, Tupasi TE. *Annals of Tropical Paediatrics* 1995;15:209-216.

### 1994

#### **Tuberculous Abscess: A Suppurative Response to *Mycobacterium tuberculosis* Infection.**

Co VM, Grimaldo ER, Rivera AB, Francisco RC, Tupasi TE.  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994*

#### **Multi-drug Resistant *Mycobacterium tuberculosis*: Role of the Fluoroquinolones.**

Francisco RC, Grimaldo ER, Rivera AB, Bautista TL, Co VM, Tupasi TE.  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994*

#### **Chronic Hepatitis B Infection in Filipinos.**

Gonzaga NC, Co VM, Maybituin SP, Tupasi TE  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994*

#### **Multicenter Study on Candida Infections.**

Sorongon ED, Pena A, Mendoza MT, Tupasi TE.  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994*

**Antibiotic Usage in Typhoid Fever in a Tertiary Hospital in Metro Manila**

Sorongon ED, Tupasi TE  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994*

**1993**

**Guidelines on Antimicrobial Therapy, 3<sup>rd</sup> edition, 1992**

Tupasi TE, Limson BM, Romero RC, Co VM, Gozali LG, Lecciones JA

***Mycoplasma Pneumoniae* and *Chlamydia Trachomatis* in Acute Lower Respiratory Infections in Filipino Children.**

Saikku P, Ruutu P, Leinonen M, Kleemola M, Paladin F, Tupasi TE  
*Am J Trop Med 1993;49(1):88-92*

**A Randomized Study of Piperacillin-tazobactam vs Cefotaxime plus Metronidazole in the Treatment of Intra-abdominal Infections.**

Co VM, Ang JC, Lazo JM, Arguelles VQ, Tupasi TE  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994:505-508*

**Drug-Resistant *Salmonella typhi***

Sorongon ED, Co RR, Co VM, Tupasi TE  
*Makati Medical Center Proceedings, 1994;VIII:29-33*

**Comparative Activities of Tosufloxacin and Other Fluoroquinolones against Common Clinical Isolates**

Baello BQ, River AB, Co VM, Tupasi TE  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994:612-613*

**In-vitro Activity of Piperacillin-Tazobactam on Piperacillin-Resistant Organisms**

Tolentino LE, Baes LC, Co VM, Lazo JM, Tupasi TE  
*4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Supplement to JAMA Southeast Asia, December, 1994: 519-521*

**1992**

**Vascular Catheter-Associated Fungemia in Patients with Cancer: Analysis of 155 Episodes.**

Lecciones LA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Wlask TJ  
*Clinical Infectious Diseases 1992;14:875-83*

**Disseminated Histoplasmosis with Unusual Cutaneous Lesions in a Patient from the Philippines.**

Navarro EE, Tupasi TE, Verardo VM, Romero RC, Tuazon CU.  
*Am J. Trop Med Hyg. 46(2), 1992*

**Is There an Emergence of Resistance with the Clinical Use of Ciprofloxacin?**

Tupasi TE, Garvez MD  
*Supplement to JAMA Southeast Asia, October 1992, 8(10): 6-9*

**Clinical Features of Life-Threatening Streptococcal Infections.**

Tupasi TE  
*Book of Abstracts, 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases.*

**Chemotherapy of Leprosy, Multidrug Therapy.**

Jacobson R, Romero RC  
*Regional Meeting on Leprosy Control, WHO, Manila, 23 June 1992*

**Squamous Metaplasia in the Respiratory Epithelium of Children Who Died of Pneumonia.**

Gonzaga NC, Anderson VM, Navarro EE, Quilepo SC  
*Book of Abstracts, 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases*

**Liver Morphology in Filipino Adults Who Are Chronic HBV Carriers.**

Gonzaga NC, Ng M, Zamuco J, Canonigo EB, Perez VN, Tolentino LE, Garvez MD, Olympia EG, Mirasol GL, Tupasi TE  
*Book of Abstracts, 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases*

**Extrapulmonary Tuberculosis in a Tertiary Hospital.**

Co VM, Francisco RC, Bautista TL, Tupasi TE  
*Book of Abstracts, 3rd Western Pacific Congress on Chemotherapy and Infectious Diseases*

**In-vitro Activity of Ciprofloxacin Against Mycobacterium Tuberculosis Resistant to Primary Antimycobacterial Agents.**

**1991**

**A CD4+CTL Clone to a Conserved Epitope on HIV-1 P24: Cytotoxic Activity and Secretion of IL-2 and IL-6**

Littau RA, Takeda A, Ennis FA  
*Journ Virology Dec 1991; 66:608-611*

**An HLA-C-Restricted CD8+ Cytotoxic-Lymphocyte Clone Recognizes A Highly Conserved Epitope on Human Immunodeficiency Virus Type 1 GAG**

Littau RA, Oldstone MB, Takeda A, Debouck C, Wong JT, Tuazon CU, Moss B, Kievits F, Ennis FA  
*Journ of Virology, August 1991;4051-4056.*

**Betalactam Resistance in Coagulase-Negative Staphylococci: Lack of Correlation with Glycocalyx Production**

Lazo JM, Baello BQ, Rivera AB, Co VM, Tupasi TE, Navarro EE

**Clinical Application of the Widal Test.**

Tupasi TE, Lucas-Aquino R, Mendoza MT, Tuazon CU, Lolekha S  
*PSMID Journal, Jan-Jun 1991; 20(1).*

**Detection of Circulating Candida Enolase by Immunoassay in Patients with Cancer and Invasive Candidiasis**

Walsh TJ, Hathorn JW, Sobel JD, Merz WG, Sanchez V, Maret M, Buckley HR, Pfaller MA,

Schaufele R, Silva C, Navarro EE, Lecciones JA, Chandrasekar P, Lee J, Pizzo PA  
*New England Journal of Medicine*. April 11, 1991; 324:1026-1031.

**Empiric Therapy with Amphotericin B in Febrile Granulocytopenic Patients.**

Walsh TJ, Lee J, Lecciones JA, Rubin M, Butler K, Francis P, Weinberg M, Rollides E, Marshall D, Gress J, Pizzo PA  
*RID* 1991; 13:496-503.

**Hemophilus Ducreyi in Genital Ulcers: Clinical and Microbiologic Features.**

Rivera AB, Baello B, Co VM, Tupasi TE, Navarro EE

**In-vitro Susceptibilities of Mycobacterium tuberculosis to Primary Antimycobacterial Agents.** Francisco RC, Littau R, Tupasi TE

**In-vitro Susceptibility to Imipenem of Gram-negative Pathogens from Nosocomial Infections at MMC.**

Baello B, Rivera A, Tupasi TE.

**Positive Urine Cultures for Candida albicans in Hospitalized Patients: Implications for Management.** Cantilep A, Espinosa M, Lecciones JA, Tupasi TE, Navarro-Almario EE

**Tuberculin Test Response of Filipino Infants Vaccinated with BCG at Birth**

Magsino-Songco MM, Pascual-Martin MR, Lecciones JA.

**Vaccinia-Virus Specific Human Cytotoxic T-cell Clones**

Littau RA, Takeda A, Ennis FA  
*Vaccines* 9:1, pp.359-36

**1990**

**Guidelines on Antimicrobial Therapy, 2<sup>nd</sup> edition, 1990**

Tupasi TE, Limson BM, Javato MC, Littau RA, Navarro EE, Lecciones JA, Gomez LO, Garvez MD, Mangubat NV, Vallente RU

**Clinical Utilization of the Quinolones: Its Impact on the Resistance Patterns of Commonly Isolated Pathogens**

Garvez MD, Francisco RC, Tolentino LE, Baes LC, Co SL, Tupasi TE

*Proceedings of a Symposium held at the 38th Annual Meeting of the Japan Society of Chemotherapy Western Branch, Gifu, Japan, 1990*

**Pathology and Clinical Aspects of Acute Respiratory Tract Infections in Children**

Gonzaga NC, Navarro EE, Lucero MG, Queipo SC, Schroeder I, Tupasi TE

*Reviews of Infectious Diseases*. Vol 12, Supp 8, Nov-Dec 1990

**Strategies for Vaccines Against AIDS**

Jaffe PA, Takeda A, Littau R, Haubrich R, Tuazon C, Ennis FA

*Phil J Internal Medicine* 1990 Jan-Feb;28:1-5

**Antimicrobial Prescribing Patterns in Hospital: Determinants and Proposed Interventions**

Javato-Laxer M, Navarro E, Littau R, Gomez ML, Tupasi TE

*The Phil J of Microbiology and Infec Dis*. Vol 18, No 2, July-December, 1989.

**The Prevalence of Chlamydia trachomatis in Cervicitis in Pregnant Females**

Javato-Laxer M, Singson R, Tolentino L, Tupasi TE, Borromeo R, Manahan CP

*The Philippine Journal of Microbiology and Infectious Diseases*. Vol 19, No. 1, Jan-June 1990

**Immune Response to Cryptosporidiosis in Philippine Children**

Laxer MA, Alcantara AK, Menorca MD, Fernando MT, Ranoa CP

*Am J Trop Med Hyg* 1990 42 (2): 131-139 (89-183)

**Catheter-associated Fungemia in Cancer Patients: Analysis of 155 Episodes**

Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall DJ, Steinberg SM

*Proceedings of the ICAAC, Houston, Texas, 1989*

**Treatment of Community-acquired Lower Respiratory Tract Infections with Oral Cefuroxime Axetil**

Limson BM, Garvez MD

*Clinical Therapeutics*. 1990; Vol. 12, No. 5:436

**Monotherapy with Pefloxacin in Multidrug Resistant Nosocomial Gram-Negative Bacteremia**

Limson BM, Pena AC, Garvez MD

*J Antimicrobial Therapy* 1990; No. 26, Suppl. 1:91-95

**Human IgG Fc Receptor II Mediates Antibody-dependent Enhancement of Dengue Virus Infection**

Littau R, Kurane I, Ennis FA

*The Journal of Immunology*. April 15, 1990; 144 (8):3183-3186

**Respiratory Rate Greater than 50 per Minute as a Clinical Indicator of Pneumonia in Filipino Children with Cough**

Lucero MG, Tupasi TE, Gomez, Beltran MG, Crisostomo AU, Romano VV, Rivera LM

*Reviews of Infectious Diseases*. Nov-Dec 1990; 12(8)

**Clinicopathologic studies of Children Who Die of Acute Lower Respiratory Tract Infections: Mechanisms of Death**

Navarro EE, Gonzaga NC, Lucero MG, Queipo SC, Schroeder I, Gomez ML, Tupasi TE

*Reviews of Infectious Diseases*. Nov-Dec 1990; 12(8)

**Hemodialysis-Hemoperfusion in Fulminant Viral Hepatitis**

Ramos CP, Almario JS

*Biomaterials, Artificial Cells and Artificial Organs*. Vol 18, No. 5, 1990

**Patterns of Acute Respiratory Tract Infection in Children: A Longitudinal Study in a Depressed Community in Metro Manila**

Tupasi TE, de Leon LE, Lupisan MS, Torres CU, Leonor ZA, Sunico ME, Mangubat NV, Miguel CA, Medalla F, Tan ST, Dayrit M  
*Reviews of Infectious Diseases. Nov-Dec 1990; 12(8)*

**Etiology of Acute Lower Respiratory Tract Infection in Children from Alabang, Metro Manila.**  
Tupasi TE, Lucero MG, Magdangal DM, Sunico ME, Torres CU, de Leon LE, Paladin JF, Baes L, Javato MC  
*Reviews of Infectious Diseases. Nov-Dec 1990; 12(8)*

**Malnutrition and Acute Respiratory Tract Infection in Filipino Children**  
Tupasi TE, Mangubat NV, Sunico ME, Magdangal DM, Navarro EE, Leonor ZA, Lupisan S, Medalla F, Lucero MG  
*Reviews of Infectious Diseases. Nov-Dec 1990; 12(8)*

**Diversity of Outer Membrane Protein Profiles of Nontypable *Haemophilus influenzae* Isolated from Children from Papua New Guinea and the Philippines**  
Weinberg GA, Lehman D, Tupasi TE, Ggranoff DM  
*Reviews of Infectious Diseases. Nov-Dec 1990; 12(8)*

**Traditional Practices and Ritual Therapy in Acute Respiratory Infection**  
Valencia LB.  
*Final Project Report to the National Research Council of the Philippines, 19*

### 1989

**Child care practices of mothers: implications for intervention in acute respiratory infections**  
Tupasi TE, Miguel CA, Tallo VL, Bagasao TMP, Natividad JN, Valencia LB, de Jesus MEG, Lupisan S, Medalla F  
*Annals of Trop Ped. 1989; 9:82-88*

**Comparative study of ciprofloxacin versus cotrimoxazole in the treatment of Salmonella enteric fever**  
Limson BM, Littaua RA  
*Jour Clin Study & Treatment 1989; Vol. 17*

**Acute suppurative thyroiditis caused by Salmonella typhi**  
Aquino RL, Navarro E, Sanieel MC  
*Phil Jour of Micro and Infect Dis. 1989; Vol 18, Jan-June.*

**Immunity to diphtheria in children in a rural community of Baclayon Municipality, Bohol**  
Trabajo E, Tupasi TE, Kaneko Y  
*Phil Jour of Micro and Infect Dis. 1989; Vol 18, Jan-June*

**Bacterial resistance and antimicrobial utilization in a Manila Hospital**  
Littaua RA, Javato MC, Tupasi TE  
*APUA Newsletter, (7) 3:1989*

***Hemophilus influenzae* from Filipino children with pneumonia.**  
Tupasi TE, de Leon LE, Kaneko Y

*Presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 1989, Houston, Texas.*

### Malnutrition and Acute Respiratory Infection

Tupasi TE, Mangubat NV, Sunico ME, Magdangal DE, Navarro EE, Leonor Z, Lupisan S, Medalla F, and Lucero MG  
*Presented at the 29th ICAAC, 17-20 September 1989 Houston, Texas and at the 11th Asia-Pacific Congress on Diseases of the Chest, 19-22 November 1989, Bangkok, Thailand*

**Etiology and Morphologic Changes in the Lungs of Children who die of Pneumonia**  
Gonzaga NC, Navarro EE, Lucero MG, Queipo SC, Schroeder I, Tupasi TE  
*Presented at the 11th Asia-Pacific Congress on Diseases of the Chest 19-22 November 1989, Bangkok, Thailand*

**Disseminated Histoplasmosis in an Immunocompromised Host**  
Navarro EE, Tupasi TE, Verallio VM, Romero RC  
*Presented at the Asian Dermatological Association Convention, 22-25 November 1989, Singapore*

**Activated EB Virus and Vaccinia Virus-specific killer cells in individuals infected with HIV-1**  
Littaua RA, Takeda A, Tuazon CU and Ennis FA  
*Presented at Virology Meeting, Cold Spring Harbor, Long Island, New York, September 1989.*

### 1988

**Guidelines on Antimicrobial Therapy, 1<sup>st</sup> edition 1988**  
Tupasi TE, Limson BM

**Acute lower respiratory tract infection associated with Chlamydial TWAR antibody in Filipino children**  
Saikku P, Ruutu P, Leinonen M, Panelius J, Tupasi TE, Grayston JT  
*L Infect Dis Nov 1988; 158(5): 1095-1097.*

**Determinants of morbidity and mortality due to acute respiratory infections: implications for intervention**  
Tupasi TE, Velmonte MA, Sanvictores MEG, Abraham L, de Leon LE, Tan ST, Miguel CA, Sanieel MC  
*J Infect Dis April 1988; 157(4): 615-623*

**Serotypes of *Streptococcus pneumoniae* and *Hemophilus influenzae* from children with pneumonia**  
Tupasi TE, de Leon LE, Kaneko Y  
*The Journal of the Japanese Association for Infectious Diseases March 1988; 62:403-404*

**Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections**  
Limson BM, Navarro E, Littaua R, Que E, Kua LT.  
*Clin Therapeutics 1988; (10)5*

### 1986-87

**Rationalizing antimicrobial use in respiratory infection: The Philippines**  
Tupasi TE, de Leon LE  
*APUA Newsletter Fall 1987; V(3): 1, 6-7*



## Participation in Conferences

### International

37<sup>th</sup> Congress of the IUATLD and Lung Disease, 2-7 October 2002 (Montreal, Canada): The DOTS-Plus Pilot Project in the Philippines  
Thelma E. Tupasi, MD

5<sup>th</sup> World TB Congress, 2-5 June 2002, Washington DC  
DOTS Plus in the Philippines  
Thelma E. Tupasi, MD

5<sup>th</sup> World TB Congress, 2-5 June 2002, Washington DC  
Failure of the w.h.o. retreatment regimen in a setting with high prevalence of multi-drug resistant tuberculosis  
Ma. Imelda Quelapio

5<sup>th</sup> World TB Congress, 2-5 June 2002, Washington DC  
The Genetic Diversity of *Mycobacterium tuberculosis* from Filipino Patients at the DOTS Clinic of the Makati Medical Center: A Preliminary Study  
Alicia R. Rivera

Annual Meeting of the STOP TB Working Group on DOTS Plus for MDR-TB. (Tallin, Estonia) 2002  
DOTS-Plus Pilot Project in MMC, Update  
Thelma E. Tupasi, MD

Annual Meeting of the STOP TB Working Group on DOTS-Plus for MDR-TB. (Lima Peru) 25-27 January 2001  
Participant and Speaker: Thelma E. Tupasi, MD  
"DOTS-Plus in the Philippines: A Multi-District Approach"

21<sup>st</sup> Conference of the IUATLD Eastern Region, Int'l Union Against TB and Lung Disease-Eastern Region, (Manila, Philippines) March 6-9, 2001  
Speaker: Thelma E. Tupasi, MD "Drug Resistant TB: Retreatment Program in Urban Setting" Moderator: Thelma E. Tupasi, MD "Controlling TB - Manila Manifesto"  
Reactor: Ma. Imelda D. Quelapio, MD to Dr. Lee Reichmann's "Defusing the Time Bomb"

10<sup>th</sup> ASEAN Pediatric Federation Conference (Malaysia) 1-4 June 2000  
Speaker: Thelma E. Tupasi, MD

7<sup>th</sup> Western Pacific Congress of Chemotherapy and Infectious Diseases (Hong Kong) 11-14 December 2000  
Speaker: Thelma E. Tupasi, MD: "TB in the Philippines"  
Participants: Ma. Imelda D. Quelapio, MD, Ma. Lourdes A. Villa, MD, Faith D. Villanueva, MD, Alicia A. Rivera, RMT, Ephraim R. Grimaldo, RMT

47<sup>th</sup> Annual Meeting of the Japan Society of Chemotherapy (Tokyo), 11 June 1999  
Speaker: Thelma E. Tupasi, MD: "Future Prospects on Quinolones"

21<sup>st</sup> International Congress for Chemotherapy (Birmingham, UK) - 7 July 1999  
Chairman: Thelma E. Tupasi, MD: Treatment of Parasitic Diseases, Lessons from Veterinary Medicine

Tazocin Pan-European Conference on Intensive Care Medicine (Baveno, Lake Maggiore, Italy) - 8-11 July 1999  
Participant: Thelma E. Tupasi, MD

1<sup>st</sup> International Congress of the Asia Pacific Society of Infection Control (APSIC) (Hongkong) - 8-11 August 1999  
Participants: Ma. Imelda D. Quelapio, MD & Mrs. Zenaida Chua, RN, ICN

39<sup>th</sup> Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) - 26-29 September 1999  
Participant: Thelma E. Tupasi, MD

Wyeth Infectious Disease Global Advisory Board Meeting (Philadelphia, USA) - 30 September 1999  
Participant: Thelma E. Tupasi, MD

### National

3<sup>rd</sup> Midyear Convention, Phil. Society for Microbiology and Infectious Diseases, (Cebu Plaza Hotel) June 22-24, 2000  
Speaker: Thelma E. Tupasi, MD: "The Phil. TB Crisis: Lessons Learned from the 1997 NTPS"

Dec. 7-9, 2000, 22<sup>nd</sup> Annual Convention, Phil. Society for Microbiology and Infectious Diseases, "From Information to Application: Bridging the Gap in the Practice of Infectious Diseases", Issues in the Management of MDR-TB in the Phil.  
The Phil. National TB Prevalence Survey, Manila Midtown Hotel

Feb. 5-7, 2001, 28<sup>th</sup> Annual Postgraduate Course, UST-Dept. of Pediatrics, "PED2001: Trends, Issues and Controversies", "Prevalence: The Current State of TB in RP"- Plenary Lecturer, CME Auditorium-Medical Bldg., UST

Feb. 7-8, 2001, 8<sup>th</sup> PIDSP Annual Convention, Pediatric Infectious Disease Society of the Philippines (PIDSPI), "Continuing Challenges in Pediatric Infectious Diseases", "Issues on Childhood TB: Prevalence of TB in RP"- Speaker, Manila Midtown Hotel

April 27, 2001, 1<sup>st</sup> PCCP Interhospital Conference, Dept. of Pulmonary Medicine-Quezon Institute, "Multidrug Resistant TB (MDRTB) Among AIDS Patients", "Course of TB in HIV Management/Clinical Outcome", Quezon Institute

June 15, 2001, 3<sup>rd</sup> Dr. Siopin L. Co Memorial Lecture, Dept. of Pharmacy Services - MMC, "Extended Spectrum Beta-lactamase (ESBL) at MMC: Implication for Control, Ledesma Hall, MMC

July 11-12, 2001, 23<sup>rd</sup> Annual Scientific Meeting, National Academy of Science and Technology, "Science in the 21<sup>st</sup> Century", Infectious Disease – Speaker, Manila Hotel

July 19-20, 2001, 11<sup>th</sup> Annual National Convention, Phil. Assoc. for Pulmonary Care, Inc. (PAPC), "Respiratory Care for the Critically and Chronically Ill", Nosocomial Infections – Speaker, Manila Galleria Suites

Aug. 16-17, 2001, 8<sup>th</sup> Annual PhilCAT Convention, Phil. Coalition Against TB (PhilCAT), "TB Diagnosis and Management: A Continuing Challenge", "Let's DOTS it! (DOTS Plus: Promise of Hope for MDR-TB)" – Speaker, Manila Midtown Hotel

Sept. 6-7, 2001, 3<sup>rd</sup> Postgraduate Course, Medical Dept. – Research Institute of Tropical Medicine (RITM), "Research and Technology in the Management of Tropical and Infectious Disease", Keynote Address, RITM Auditorium, Alabang, Muntinlupa City

September 2001, Orillaza RB. DOTS in the Management of TB. University of the Philippines-Philippine General Hospital Family Medicine Department

Quelapio MID. Involving the Private Sector in DOTS. Friendly Care Physicians, June 2001.

Sept. 6-8, 2001, 13<sup>th</sup> Midyear Convention, Phil. Academy of Family Physicians-Cebu Chapter, "New Horizons in Clinical Care: Strengthening Family Practice", "PTB Clinical Practice Guidelines Recommendations", Waterfront Hotel Lahug, Cebu City

Oct. 12-14, 2001, 5<sup>th</sup> Workshop – Dept. of Pediatrics, Dept. of Pediatrics-MMC, Current Advances in TB Pediatrics, Punta Baluarte, Calatagan, Batangas City

Oct. 13, 2001, Dialogue, Integrated PHO-DOH, Lucena City, "Mobilizing Private Practitioners as Project Partners", Resource Speaker, Halina Hotel, Lucena City  
Speakers: Thelma E. Tupasi: "TB in the Philippines and What the Private Sector has Done"; Ma. Imelda D. Quelapio, MD: "DOTS in the Private Setting"

Oct. 25-26, 2001, 13<sup>th</sup> Mid-Year Convention, Phil. College of Physicians, "Old Issues, New Concepts", "Antibiotic Resistance: The Challenge of the Superbugs", Waterfront Cebu City Hotel

Nov. 1-4, 2001, 32<sup>nd</sup> World Conference on Lung Health, International Union Against Tuberculosis and Lung Disease (IUATLD), "TB Education Course and Workshop", Palais des Congrès, Porte Maillot, Paris, France

Nov. 16, 2001, Dr. Jose Albert Annual Memorial Lecture, UP-PGH Department of Pediatrics, Overview of Philippine Childhood Tuberculosis, PGH, Manila

Nov. 29 – Dec. 1, 2001, 23<sup>rd</sup> Annual Convention, Phil. Society for Microbiology and Infectious Diseases, "New Paradigms in Infectious Diseases: Relevance to Clinical Practice", Changing Epidemiology of

Infectious Diseases: MDR-TB, Westin Philippine Plaza Hotel, Manila

**Regional Seminar – Workshop on Leptospirosis (University of the Philippines, Manila) – 22 January 2000**

Participants: Thelma E. Tupasi, MD, Ma. Imelda D. Quelapio, MD, Ma. Lourdes A. Villa, MD, Faith D. Villanueva, MD, Benilda Q. Baello, RMT, Alicia A. Rivera, RMT, Rowena C. Cardaño, RMT, Jerose O. Derilo, RMT

**Seamic National Group Training Course on Laboratory Diagnosis of Dengue (Bureau of Research and Laboratories, DOH) – 7-11 February 2000**

Participant: Ma. Socorro M. Clarin, RMT

**Biosafety Measures and Precautions on the use of P3 Laboratory (Traders Hotel and STD/AIDS Cooperative Laboratory) – 10-11 April 2000**

Participant: Ma. Socorro M. Clarin, RMT

**Training Workshop on Infection Control for Infection Control Link Nurses (Makati Medical Center) – 14 April 2000**

Lecturers: Rodrigo L.C. Romulo, MD, Margarita T. Cayco, MD, Homer G. Abiad, MD, Ma. Imelda D. Quelapio, Carmela A. Rivera, MD, Faith D. Villanueva, MD, Ms. Zenaída A. Chua, RN

**30<sup>th</sup> Annual Convention of the Philippine College of Physicians (EDSA Shangri-La Hotel) – 9-12 May 2000**

Participants: Thelma E. Tupasi, MD, Ma. Imelda D. Quelapio, MD, Ma. Lourdes A. Villa, MD, Faith D. Villanueva, MD

**Infection Prevention in the Workplace...2000 (Sulu Hotel, Manila) – 11 May 2000**

Participant: Zenaída A. Chua, RN

**6<sup>th</sup> Annual Convention of the Philippine Hospital Infection Control Society, Inc. Occupational Safety and Health Center, Diliman, Quezon City) – May 2000**

Lecturer: Ma. Imelda D. Quelapio, MD: "Ventilator-Associated Pneumonia: Prevention"  
Participant: Zenaída Chua, RN

**Philippine Association of Central Services and Sterilization Management 1<sup>st</sup> Annual Convention (Camp Gen. Emilio Aguinaldo, Quezon City) – 1-2 June 2000**

Participant: Zenaída A. Chua, RN

**Infectious Diseases Forum VI (Asturias Hotel, Puerto Princesa Palawan) – 2-4 June 2000**

Participant: Faith D. Villanueva, MD

**3<sup>rd</sup> Midyear PSMID Convention (Cebu Plaza Hotel) 22-24 June 2000**

Workshop on DOTS: "DOTS Basic Course"; "Setting up a DOTS Clinic: MMC Experience"; "Lessons Learned at the MMC Clinic"; "Sputum Microscopy"  
Lecturers: Ma. Imelda D. Quelapio, MD, Alicia B. Rivera, RMT, Nona Rachel C. Mira, RN

Lecturer: Thelma E. Tupasi, MD: "Penicillin – A Romance Revisited"  
Lecturer: Vilma M. Co, MD: "Carbapenems in Nosocomial Infections"  
Lecturer: Faith D. Villanueva, MD: "Antibiotic Therapy in the Allergic Patient"

**7<sup>th</sup> Annual Convention of the Philippine Coalition Against Tuberculosis (Manila Midtown Hotel) – 20-21 August 2000**

Lecturer: Thelma E. Tupasi, MD: "Private-Public DOTS: MMC DOTS Clinic" Participants: Ma. Lourdes A. Villa, MD, Faith D. Villanueva, MD, Nona Rachel Mira, RN, Michael Abeleda, RN

**Philippine Society for Microbiology and Infectious Diseases. Second Fellows' Clinico-Pathologic Inter-Hospital Conference (Makati Medical Center) – 12 September 2000**

Presenter: Faith D. Villanueva, MD  
Reactor: Thelma E. Tupasi, MD

**Infectious Diseases Forum (Makati Medical Center) – 3 October 2000**

Lecturer: Thelma E. Tupasi, MD: "Multi-drug Resistant Tuberculosis in the Philippines"  
Lecturer: Vilma M. Co, MD: "Hepatitis B Infection: What you might have heard about it and what you should know"  
Lecturer: Ma. Imelda D. Quelapio, MD: "The MMC DOTS Clinic"

**2<sup>nd</sup> Subspecialty Postgraduate Course in Perinatology and Neonatology (Children's Medical Center of the Philippine & General Hospital, Inc.) - 27 May 1999**

Speaker: Thelma E. Tupasi, MD: "Infections in Pregnancy and the Neonatal Period (TB, Hepatitis, Dengue, HIV)"

**5<sup>th</sup> Annual Convention on Infection Control (PHICS): "Common Sense in Infection Control" (Occupational Safety and Health Center, Diliman, Quezon City) - 27-28 May 1999**

Participants: Ma. Imelda D. Quelapio, MD & Mrs. Zenaida Chua, RN, ICN

**St. Luke's Lecture for the Month - 16 June 1999**

Speaker: Thelma E. Tupasi, MD:  
"Pharmacokinetics and Judicious Use of Antibiotics"

**4<sup>th</sup> CPE Seminar of the Philippine Association of Medical Technologists (PAMET) - Emilio Aguinaldo Colleges, Taft Avenue, Manila - 12 August 1999**

Speaker: Thelma E. Tupasi, MD: "The 1997 National Tuberculosis Prevalence Survey"  
Speaker: Alice B. Rivera, RMT: "Drug-Resistant Tuberculosis in the Philippines"

**3<sup>rd</sup> Orthopedic Symposium (Department of Orthopedics, Makati Medical Center) - 27 August 1999**

Speaker: Thelma E. Tupasi, MD: "Tuberculous Arthritis"

**Seminar Workshop on The Streptococcal Menace: Prevention and Control of Rheumatic Fever and Rheumatic Heart Disease (EDSA Shangri-La Hotel) – 7-8 October 2000**

Lecturers: Thelma E. Tupasi, MD, Homer G. Abiad, MD, Faith D. Villanueva, MD, Ery T. Limlingan, MD, Benilda Q. Baello, RMT, Ma. Socorro M. Clarin, RMT

**22<sup>nd</sup> Annual Convention of the Philippine Society for Microbiology and Infectious Disease (Manila Midtown Hotel) 7-9 December 2000**

Lecturer: Thelma E. Tupasi, MD: "1997 Nationwide Tuberculosis Prevalence Survey"

Lecturer: Vilma M. Co, MD: "Toxic Shock Syndrome"  
Lecturer: Ma. Imelda D. Quelapio, MD: "Corporate DOTS"

Participants: Ma. Lourdes A. Villa, MD, Faith D. Villanueva, MD, Ery T. Limlingan, MD, Nona Rachel C. Mira, RN, Michael R. Abeleda, RN, Virgil A. Belen, RN

**18<sup>th</sup> Annual Chest Convention (EDSA Shangri-La Hotel) - 5 March 1999**

Speaker: Thelma E. Tupasi, MD: "Sequential Switch Therapy in LRTI"

**8<sup>th</sup> Postgraduate Course on Internal Medicine (Our Lady of Lourdes Hospital) - 18 March 1999**

Speaker: Thelma E. Tupasi, MD: Antibiotic Pharmacodynamics/ Judicious Use of Antibiotics"

**DOH Training for Trainors on DOTS (Manila) (Park View Hotel, Paco, Manila) – 4-8 October 1999**

Participants: Ma. Imelda D. Quelapio, MD, Nona Rachel B. Mira, RN, Michael Abeleda, RN

**12<sup>th</sup> Midyear Convention of the Philippine College of Physicians (Iloilo City) - 9 October 1999**

Speaker: Thelma E. Tupasi, MD: "Use and Misuse of Antibiotics"

**3<sup>rd</sup> Regional Convention of the Philippine Society for Microbiology and Infectious Diseases, Visayas Chapter (Iloilo City) - 21 October 1999**

Keynote Lecture: Thelma E. Tupasi, MD: "The Tuberculosis Problem in the Philippines"

**7<sup>th</sup> Annual Postgraduate Course of the Philippine College of Physicians, Central and Eastern Visayas Chapter (Cebu City) - 6 November 1999**

Speaker: Thelma E. Tupasi, MD: "Penicillin: a Romance Rekindled"

**21<sup>st</sup> Annual Convention of the Philippine Society for Microbiology and Infectious Diseases (Westin Philippine Plaza Hotel) - 2 December 1999**

Reactor: Thelma E. Tupasi, MD: "Updates on the Management of Antimicrobial Resistance"  
Lecturer: Thelma E. Tupasi, MD: "Penicillin: How Useful in Respiratory Streptococcus pneumoniae"  
Lecturer: Ma. Imelda D. Quelapio, MD: "A Double-Blind Study Comparing the Safety and Efficacy of Cefepime versus Ceftazidime in Severe Bacterial Infections"

# Carlos J. Valdes & Associates

certified public accountants

Carlos J. Valdes Bldg.  
108 Aguirre St. Legaspi Village  
Makati City, Philippines

Branches: Cebu and Davao

Telephone  
(632) 892-5931 to 35  
(632) 819-1468  
(632) 750-7563  
Facsimile (632) 819-1468  
e-mail: cjva@i-next.net

# CJVA

## INDEPENDENT AUDITOR'S REPORT

### The Board of Trustees TROPICAL DISEASE FOUNDATION, INC.

Makati Medical Center  
# 2 Amorsolo St. Makati City

We have audited the accompanying balance sheet of **TROPICAL DISEASE FOUNDATION, INC.** (*A Non-Stock, Non-Profit Corporation*) as of December 31, 2003 and the related statements of revenues and expenses, changes in fund balance and cash flows for the year then ended. These financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards in the Philippines. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the 2003 financial statements referred to above present fairly, in all material respects, the financial position of **TROPICAL DISEASE FOUNDATION, INC.** (*A Non-Stock, Non-Profit Corporation*) as of December 31, 2003, and the results of its operations and its cash flows for the year then ended in conformity with generally accepted accounting principles in the Philippines.

  
C. M. ENRIQUEZ

Partner

CPA Certificate No. 031628

PTR No. 7014784 - 01/06/04

PRC-BOA Reg. No. 0314

Issued on Nov. 3, 2003

Valid until Nov. 3, 2006

Makati City, Philippines

February 11, 2004

# TROPICAL DISEASE FOUNDATION, INC.

(A Non-Stock, Non-Profit Organization)

## BALANCE SHEETS

(In Philippine Peso)

	December 31
<b>A S S E T S</b>	<b>2003</b>
<b>CURRENT ASSETS</b>	
Cash (Note 2 )	80,415,139
Short term investments, net (Note 3)	1,148,051
Advances	190,153
Prepaid rent	16,842
Total current assets	<u>81,770,185</u>
<b>NON-CURRENT ASSETS</b>	
Property and equipment, net (Notes 2 and 4)	15,886,340
Refundable deposits	752,304
Total non-current assets	<u>16,638,644</u>
<b>TOTAL ASSETS</b>	<u><u>98,408,829</u></u>
<b>LIABILITIES AND FUND BALANCE</b>	
<b>CURRENT LIABILITIES</b>	
Accounts payable and accrued expenses	4,180,322
Due to sub-recipients (Note 6)	64,131,145
Total current liabilities	<u>68,311,467</u>
<b>NON-CURRENT LIABILITIES</b>	
Funds held in trust (Note 7)	8,775,386
<b>FUND BALANCE</b>	<u>21,321,976</u>
<b>TOTAL LIABILITIES AND FUND BALANCE</b>	<u><u>98,408,829</u></u>

*See Notes to Financial Statements*

**TROPICAL DISEASE FOUNDATION, INC.**

*(A Non- Stock, Non-Profit Organization)*

**STATEMENTS OF RECEIPTS AND EXPENSES**

*(In Philippine peso)*

---

<b>For the Years Ended December 31,</b>	<b>2003</b>
<b>RECEIPTS</b>	
Donations and contributions (Note 8)	28,544,048
Fund raising	74,500
Other income	292,899
Total revenues	<u>28,911,447</u>
<b>EXPENSES</b>	
Salaries and wages	3,002,288
Medicine	2,438,319
Depreciation	1,890,048
Laboratory and office supplies	1,707,198
Transportation and travel	1,638,772
Unrealized foreign exchange loss	742,301
Seminars and trainings	498,879
Representation	474,064
Retirement	443,220
Communication	428,304
Insurance	343,830
Contractor's fee	288,092
Utilities	167,257
Repairs and maintenance	127,404
Donation	120,000
Professional fees	100,572
Taxes and licenses	73,706
Interest, net	61,735
Provision for probable losses on investment	49,223
Miscellaneous	280,607
Total expenses	<u>14,875,819</u>
<b>EXCESS OF RECEIPTS OVER EXPENSES</b>	<u><b>14,035,628</b></u>

---

*See Notes to Financial Statements*

**TROPICAL DISEASE FOUNDATION, INC.**

*(A Non- Stock, Non-Profit Organization)*

**STATEMENT OF CHANGES IN FUND BALANCE**

*(In Philippine peso)*

	<b>Fund Balance</b>
<b>BALANCE AS OF DECEMBER 31, 2001</b>	5,147,904
Deficit for the year ending December 31, 2002	<u>(1,087,286)</u>
<b>BALANCE AS OF DECEMBER 31, 2002</b>	4,060,618
Excess of receipts over expenses for the year ending December 31, 200	14,035,628
Prior period adjustments	<u>3,225,730</u>
<b>BALANCE AS OF DECEMBER 31, 2003</b>	<b><u>21,321,976</u></b>

*See Notes to Financial Statements*

**TROPICAL DISEASE FOUNDATION, INC.**

*(A Non-stock, Non-profit Organization)*

**STATEMENT OF CASH FLOWS**

*(In Philippine Peso)*

---

<b>For the Fiscal Year Ended December 31,</b>	<b>2003</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>	
Excess of receipts over expenses	14,035,628
Adjustment to reconcile net income to cash	
Depreciation	1,890,048
Provision for probable losses on investment	49,223
Prior period adjustment	3,225,730
	<hr/>
Operating income before working capital changes	19,200,629
(Increase) Decrease in:	
Advances	(58,829)
Prepaid rent	(16,842)
Refundable deposits	(130,670)
Increase (Decrease) in:	
Accounts payable and accrued expenses	4,192,675
Due to sub-recipients	64,131,145
Plan liabilities	(1,257,322)
	<hr/>
Net cash used in operating activities	86,060,786
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>	
Investment	1,664,684
Acquisition of property and equipment	(16,658,312)
Funds held in trust	8,775,386
	<hr/>
Net cash used in investing activities	(6,218,242)
<b>NET DECREASE IN CASH AND CASH EQUIVALENTS</b>	<b>79,842,544</b>
<b>CASH AND CASH EQUIVALENTS, BEGINNING</b>	<b>572,595</b>
<b>CASH AND CASH EQUIVALENTS, ENDING</b>	<b>80,415,139</b>

---

*See Notes to Financial Statements*



**TROPICAL DISEASE FOUNDATION, INC.**  
*(A Non-stock, Non-profit Organization)*

**NOTES TO FINANCIAL STATEMENTS**  
*December 31, 2003*

**NOTE 1 – ORGANIZATION**

**TROPICAL DISEASE FOUNDATION, INC. (formerly TROPICAL DISEASE RESEARCH FOUNDATION, INC.)** is a non-stock, non-profit organization organized and existing under the laws of the Republic of the Philippines and is duly registered with the Securities and Exchange Commission. It was founded November 5, 1984 as a scientific institution committed to undertake biological research and provide training and service in the control and management of tropical infectious diseases.

As a non-stock, non-profit scientific institution, it is exempt from taxes as mandated by paragraph 3, Section 4 Article XIV of the 1987 Constitution. The Foundation is an accredited and registered donee institution by the Philippine Council for NGO Certification (PCNC). As such, its donors are entitled to full or limited deduction or, and exemption from donor's tax.

Its registered address is located at Metro Manila Philippines and it has thirty (30) regular employees as of December 31, 2003.

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES**

**2.1. Basis of financial statements preparation** – The accompanying financial statements have been prepared in accordance with the generally accepted accounting principles in the Philippines based on the historical cost convention.

**2.2. Adoption of revised and new standards** – The Company has adopted and applied the following revised and new standards for financial statements preparation beginning on or after January 1, 2002 and 2003.

**Effective 2002**

	:	Framework for the preparation and presentation of financial statements
SFAS 1/ IAS 1	:	Presentation of financial statements (revised 2000)
SFAS 13/ IAS 8	:	Net income or loss for the period, fundamental errors and changes in accounting policies
SFAS 16/ IAS 16	:	Property, plant and equipment

<b>NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES, continued</b>
--

SFAS 18	:	Summary of Generally Accepted Accounting Principles on Stockholders' equity
SFAS 22/ IAS 7	:	Cash flows statements (revised 2000)
SFAS 28/ IAS 18	:	Revenue

**Effective 2003**

SFAS 10/ IAS 10	:	Events after the balance sheet date
-----------------	---	-------------------------------------

**2.3. Cash on hand and in banks** – Cash is valued at face amount as provided for by SFAS 2 – Summary of Generally Accepted Accounting Principles on Cash.

**2.4. Short-term investments** - The organization's short-term investments are carried at the lower of its aggregate cost or market value determined at the balance sheet date. The amount on which aggregate cost or market exceeds market value is accounted for as allowance for decline in value.

**2.5. Property and equipment** – Property and equipment are valued at cost less accumulated depreciation. Depreciation is computed using the straight – line method over the estimated useful lives of the depreciable assets. Additions, betterments, and major replacements are capitalized while minor repairs and maintenance are charged to expenses as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income for the year.

The Foundation's management periodically monitors the conditions of the property and equipment as well as the depreciation method used and the estimates on related useful lives to ensure that estimates adopted represent the actual situation. The Foundation likewise assures that if any variation exists between the estimates and the actual scenario, it will have an immaterial effect on the financial statements.

Provisions of SFAS/ IAS 16 on property and equipment are strictly implemented and observed by the Foundation.

**2.6. Revenue and expense recognition**

The organization uses the accrual basis for accounting its income and expenses. Under this method, income is recognized when earned and expenses when incurred.

### NOTE 3 – SHORT TERM INVESTMENTS

This account includes various investments in stocks, both locally and internationally traded.

Cost	₱ 1,197,274
Less: Allowance for decline in value	<u>49,223</u>
Net realizable value	<u>₱ 1,148,051</u>

### NOTE 4 - PROPERTY AND EQUIPMENT

The details of property and equipment are as follows:

	Condominium	Leasehold Improvements	Laboratory, Office Equipment	Transportation, Furniture & Fixture	Total
<b>Cost</b>					
Dec. 31, 2002	₱ -	₱ -	₱ 8,172,589	₱ 689,573	₱ 8,862,162
Additions	5,486,436	3,798,376	3,580,879	3,792,620	16,658,311
Disposals	-	-	3,535,375	142,323	3,677,698
Dec. 31, 2003	<u>5,486,436</u>	<u>3,798,376</u>	<u>8,218,093</u>	<u>4,339,870</u>	<u>21,842,775</u>
<b>Accumulated depreciation</b>					
Dec. 31, 2002	-	-	7,054,585	689,500	7,744,085
Provisions	183,096	165,652	1,353,540	187,760	1,890,048
Disposals	-	-	3,535,375	142,323	3,677,698
Dec. 31, 2003	<u>183,096</u>	<u>165,652</u>	<u>4,872,750</u>	<u>734,937</u>	<u>5,956,435</u>
<b>Net book value</b>					
Dec. 31, 2003	<u>₱ 5,303,340</u>	<u>₱ 3,632,724</u>	<u>₱ 3,345,343</u>	<u>₱ 3,604,933</u>	<u>₱ 15,886,340</u>

Depreciation charged to operations during the year amounted to ₱1,890,048.

### NOTE 5 – RETIREMENT PLAN

The organization has a trustee, non-contributory retirement plan which covers substantially the organization's regular employees. Normal retirement is upon attainment of age sixty (60) and employee has been in service for twenty (20) years. The plan is handled by the Trust Division of the Standard Chartered Bank. Total amount provided for during the year amounted to P443,220.

**NOTE 6 – DUE TO SUB-RECIPIENTS**

This account consists of the following:

Philippine Rural Reconstruction Movement (PRRM)	₱ 38,426,385
DOTS-Plus	15,347,500
Philippine Coalition Against Tuberculosis (PHILCAT)	6,680,308
World Vision Development Foundation, Inc. (WDFI)	2,599,953
Department of Health (DOH)	<u>1,076,999</u>
Total	<b>₱ 64,131,145</b>

**NOTE 7 – FUNDS HELD IN TRUST**

These funds are entrusted to the organization and are restricted as to its utilization. When used for procurement of property and equipment that will benefit the organization, these are recognized as Donated income.

**NOTE 8 – DONATIONS AND CONTRIBUTIONS**

This account is detailed as follows:

Global Fund	₱ 13,763,576
National Institute of Health	4,432,709
Mayo Clinic - Tuberculosis Transmission	2,796,141
Case Western Reserve University Fund	2,341,740
World Health Organization – RCS DOTS	1,875,755
Others	<u>3,334,127</u>
Total	<b>₱ 28,544,048</b>

## NOTE 9 – OTHER MATTERS

### 1. Contracts

#### A. Global Fund to Fight AIDS, Tuberculosis and Malaria

During the year, the Foundation entered into a program grant agreement with the Global Fund to Fight Aids, Tuberculosis and Malaria (Global Fund) for the implementation or overseeing the implementation of two (2) programs e.g. Accelerating the Response to Tuberculosis under Grant no. PHL-202-G02-T-00 and Accelerating the Response to Malaria under Grant no. PHL-202-G02-M-00. Both grants started on July 1, 2003 and end on June 30, 2005 and proposed completion date is on June 30, 2008.

#### B. Case Western Reserve University (CWRU)

The Research Consortium Agreement between CWRU and the foundation which is sponsored by the National Institute of Health under project title “Tuberculosis Research Unit “ (TBRU) is a collaborative effort between the two (2) organizations wherein the foundation agreed to use its personnel, facilities and reasonable efforts in the performance of work in exchange for costs reimbursement based on an agreed budget. Program started on November 15, 2003 and continue through November 30, 2004.

### 2. Approval of Financial Statements

These financial statements were approved for issuance by the Company’s duly authorized representative, Thelma Tupasi, President, for the year ending December 31, 2003 on April 6, 2004.

## Tropical Disease Foundation, Inc.

### Board of Trustees

#### *Chairperson Emeritus*

Raul G. Fores, M.D.  
Medical Director & Executive Vice-President  
Makati Medical Center

#### *Chairperson*

Ambassador Bienvenido Tan  
Philippine Business for Social Progress

#### *Members*

Mercedes B. Concepcion, Ph.D.  
Prof. Emeritus & Former Dean  
Population Institute  
University of the Philippines  
Florina Kaluag, M.D.  
Head, Cardiology Section  
Makati Medical Center  
Manuel Lazaro, LL.B  
MM Lazaro Law Offices

Vitaliano N. Nanagas  
Chairman, Development Bank of the  
Philippines

Ma. Imelda D. Quelapio, M.D.  
Executive Officer, MMC DOTS Clinic

Claver P. Ramos, M.D.  
Head, Nephrology Section  
Makati Medical Center

Roberta C. Romero, M.D.  
Dermatology  
Philippine Children's Medical Cent

Florentino S. Solon, MD  
Executive Director  
Nutrition Center of the Philippines

Thelma E. Tupasi, M.D.  
Head, Infectious Disease Section  
Makati Medical Center

Edmundo Villacorta, MD  
Vice President for Medical Services  
Makati Medical Center

### International Advisory Board

#### *Honorary Chairman*

Calvin M. Kunin, M.D.  
Pomerene Professor of Medicine  
Ohio State University  
Columbus, Ohio, USA

#### *Members*

Carmelita U. Tuazon, M.D.  
Professor of Medicine  
Biostatistics  
George Washington University  
Washington, D.C., USA

Sistla Radhakrishna, Ph.D  
Retired Director, Institute of  
TB Research Council  
Mumbai, India

### Institutional Review Board

#### *Chairperson*

Claver P. Ramos M.D.

#### *Co-Chairperson*

Miriam Davis

#### *Members*


Dennis Damaso, M.D.  
Normita Leyesa, BSP Pharm  
Romana Borromeo, M.D.

Claver P. Ramos, M.D.  
Florentino S. Solon, M.D.  
Thelma E. Tupasi, MD

Saturnino Javier, MD  
Rev. Fr David Turnbull, OSF.  
Nellie Mangubat, BSFT

Vilma Co, MD  
Human Subjects Administrator

**ORGANIZATIONAL CHART**



1



2



3



4



5



6

1. The Green Light Committee (GLC) members, Drs. Ernesto Jaramilla and Kitty Lambregts, discuss with the TDF staff their findings on the implementation of the MMC-DOTS Plus program during their visit on December 9-12, 2003.

2. Dr. Thelma E. Tupasi is shown conducting the DOTS-Plus Implementation Training Modules for Makati Health Physicians at the Makati City Hall on December 17, 2003.

3. Implementation of directly observed oral intake of anti-TB drugs in the community and in the clinic.

4. Ms. Dana Jankus, data manager of Case Western Reserve University, during her visit on November 17-21, 2003, conferring with Nellie Mangubat of TDF and the MMC pharmacists, Ms. Normita Leyesa & Michael Arabit.

5. Spectrum culture examination in the laboratory.

6. Processing of specimens in the safety hood



## Benefactors

*We acknowledge with deep gratitude the benefactors, patrons, sponsors, donors and friends of the Foundation.*

### Memorial endowments in honor of:

CONSTANTINO P. MANAHAN, M.D.  
*Director & Chairman of the Board  
Makati Medical Center  
Chairman, Board of Trustees  
Tropical Disease Foundation*

LUCRECIA LIZARES GUSTILO  
*Beloved wife of Romeo H. Gustilo, M.D.*

### Benefactors:

Asia Brewery Scholarship  
Foundation  
AstraZeneca  
Bayer Philippines, Inc.  
Bristol-Myers Squibb-Mead  
Johnson (Phil), Inc.  
United Laboratories, Inc.  
Daiichi Selyaku Co., Ltd  
E.R. Squibb & Sons (Phil.) Corp  
Insular Life Assurance Co, Ltd.  
Phil. Investment Management  
Consultants Inc.  
(PHINMA)  
Schering Corp. (Phil.), Inc.  
Mr. Lucio C. Tan  
Dr. & Mrs. Claver Ramos  
Zuellig Pharma Corporation  
Florina Kaluag, M.D.  
Oscar L. Liboro, MD.  
Ambassador & Mrs. Ramon del  
Rosario  
Tan Yan Kee Foundation  
Glaxo-SmithKline  
Nutrition Center of the  
Philippines

### Patrons:

BOIE-Takeda Chemicals, Inc  
Carlos Palanca Foundation  
Dona Kingpaoguat Typoco  
Tanyu  
Far East Bank and Trust Co.  
Trans-Philippines Investment  
Corporation  
Stephen Fuller, M.D.  
Romeo H. Gustilo, M.D.  
Miguel de Leon, M.D.  
Fmr. Senator & Mrs. Manuel  
Manahan  
Dr. & Mrs. Roel Romero  
Glocrito Sagisi, M.D.  
Mr. Harry Tan  
Mrs. Carmen Yulo

Elena P. Tan Foundation  
Philippine Cut Flower Corp.  
Sen. Loren Legarda  
Pablo Antonio Jr. Design  
Consultancy, Inc.  
Eli-Lilly (Phils) Inc.  
Dr. Thelma Crisostomo  
Lapanday Foods  
Esicor Inc.  
Boysen  
Wyeth Philippines Inc.  
Zuellig Pharma Corp.  
Bayer Philippines, Inc.  
Servier Phils.  
Abbott Laboratories  
Stars Bar and Dining  
AIC Realty Corporation

### Sponsors:

Dr. Raul Fores  
Col. & Mrs. Juan Arroyo  
Normando C. Gonzaga, M.D.  
Mr. Jun Ichinose  
Rebecca Singson, M.D.  
Engr. Proceso P. Ramos  
M.M. Lazaro and Associates  
Dr. & Mrs. Vicente Magsino  
Cathay Drug Company, Inc.  
Cordillera Savings & Loan Bank  
Otsuka Pharmaceuticals  
Philippines  
Roche Philippines Inc.  
Avon Cosmetics, Inc.  
Microbase Inc.  
David M. Consunji  
N.L. Villa Medical Center  
Highlight Metal Craft  
SANOFI Winthrop, Inc.  
Asia Industries, Inc.  
Atty. & Mrs. Zoilo Dejaresco  
LEC Steel Marketing  
Bank of Commerce  
Max's Restaurant  
Pfizer

Asia Industries Material  
Handling  
Equipment Corp.

### Donors:

Counsellor's Inn  
Mr. Hubert d' Aboville  
Ms. Nina Aquino  
Mr. & Mrs. Juanito de Dios  
Mrs. Lillian de Leon  
Mrs. Asuncion G. Aviado  
Mr. Johnny Matanagmon  
Reynaldo Que  
Mr. Joey Reyes  
Vermen Verallo, M.D.  
Angela Villanueva, M.D.  
Atty. & Mrs. Rafael Borromeo  
Dr. Lourdes Manahan  
Dr. Floro Brosas  
Annie & Rudy Sim  
Dr. & Mrs. Alipio Abad  
Rural Bank of Solano  
Dr. and Mrs. Renato Sibayan  
The American Eye  
Antonio & Regina Alvarez  
Mariposa Foundation, Inc.  
Dr. Jose Paolo Lorenzo  
Dr. Carmelita Grande  
Makati Heart Foundation  
Sen. Juan Ponce Enrile  
Mr. & Mrs. Alex Villamar  
Beta Electric Corp.  
Transworld Rubber  
Alpha Plumbing Works  
Gerald & Daniel Quelapio  
Dr. & Mrs. Dante B. Moraes  
General Offset Press inc  
3M Philippines  
VMV Hypoallergenic  
George and Grace Ramos  
Mr. Vince Garcia

### Institutional Donors

Frontline Linkage Incorporated  
New World Sales Center  
Sycip, Gorres, Velayo & Co.

## Friends of the Foundation

- Miss Asuncion M. Albert  
 Mr. & Mrs. Chester Babst  
 Jose Lopez David, M.D.  
 Arch. Santiago Esplana  
 Arch. & Mrs. Willi Fernandez  
 Atty. & Mrs. Joselin Fragada  
 Dr. Yoshio Hamaguchi  
 Mr. & Mrs. Bernardo Jalandoni  
 Eduardo Jamora, M.D.  
 Mr. & Mrs. Precha Kulapongse  
 Mr. Horacio Pascual  
 Mrs. Beatrice Sim  
 Engr. Antonio Simpao  
 Arch. & Mrs. Greg Timbol  
 Mr. & Mrs. Adolfo Villegas  
 Mr. Antonio Yap  
 Mr. & Mrs. Jose Yuzon  
 FC Masagana Bld.  
 Kidney Unit, Makati Medical  
 Center  
 Mg Man To  
 R. & T. Rodriguez  
 A & S Hardware  
 Bacnotan Consolidated  
 Industries, Inc.  
 Bataan Pulp and Paper Mills  
 Dermhaus  
 EMAR Corporation  
 Trans-Asia Oil and Mineral  
 Development Corp.  
 Internationale Foundation, Inc.  
 Unimer Trading Corporation  
 United Pulp and Paper  
 Corporation  
 Victorias Marketing  
 Dr. Patricia Santos  
 Dr. Clemente Gatmaitan  
 Dr. Eloisa Pastores  
 Dr. Gary Lopez  
 Dr. Bienvenido Aldanese  
 Dr. Annabelle Aherrera  
 Dr. John Pastores  
 Dr. Thelma Leelin  
 Dr. Arnel Diaz  
 Dr. Bienvenido Cabral  
 Dr. Nora Figueroa-Santos  
 Dr. Filomena Montinola  
 Dr. Benjamin Luna  
 Dr. Benjamin Bince  
 Dr. Antonio Cayco  
 Dr. Ludivina Garces  
 Dr. Rosario Paguntalan  
 Marissa Rovillos  
 Dr. Wilma Baltazar  
 Dr. Theresa Ortin  
 Dr. Ruth Divinagracia  
 Dr. Victor Lopez  
 Dr. Roberto Ingles  
 Dr. Dindo Isabela  
 Dr. Estela Cabrera  
 Dr. Juliet Yap  
 Dr. & Mrs. Michael Wassmer  
 Philippine Orthopedic  
 Institute  
 Dr. Agripino Reloza  
 Dr. Angelita Aguirre  
 Dr. Ma. Teresa Tangkeko  
 Dr. Zenaida Bagabaldo  
 Dr. Eduardo Jamora  
 Dr. Jaime Lapuz  
 Dr. Elaine Baens Araneta  
 Dr. Saturnino Javier  
 Dr. Santos Ocampo  
 Dr. Emmanuel Ibay  
 Dr. Jacqueline King  
 Dr. Elsie Floreza  
 Dr. & Mrs. Roberto Mata  
 Mr. William Co  
 Dr. Jose San Gabriel  
 Dr. Oswald Herrera  
 Susan Lamb  
 Dr. Augusto Litonjua  
 Dr. Sylvia Jamora  
 Dr. Imelda Villar  
 Dr. Benjamin Magsino  
 Dr. Gregorio Martinez  
 Dr. Milan Tambunting  
 Dr. Alexis Reyes  
 Dr. Carmela Isabela  
 Dr. Nazario Macalintal  
 Dr. Josephine Raboca  
 Dr. Eduardo Rondain  
 Dr. Gerardo Beltran  
 Dr. Benjamin Adapon  
 Dr. Jack Arroyo  
 Maribel Rivera  
 Dr. Tito Torralba  
 Dr. Edmundo Villacorta  
 Dr. Cristina Antonio  
 Enrique & Susana Campos  
 Dr. Martesio Perez  
 Dr. Ramon Ocampo  
 Dr. Homobono Calleja  
 Dr. Deogracias Custodio  
 Dr. Johnny Almirante  
 Dr. Mercy Viduya  
 Dr. Simon Sawit  
 Dr. Federico Leelin  
 Dr. Ramon Ongsiako  
 Dr. Shirley Ong  
 Conchita Morales  
 Mary Lou Claudio  
 Dr. Ariston Bautista  
 Gerald Panlilio  
 Henry & Lucy Co  
 Ma. Chuatico  
 Dr. Esther Leynes  
 Saudi Ambassador Al-  
 Ghandi  
 Dr. Benjamin Famador  
 Dr. Erlinda Famador  
 Dr. Reynaldo Rivera  
 Dr. Conrado Lorenzo  
 Dr. May Sison  
 Dr. Bernardo Cueto  
 Philippine Orthopedic  
 Institute  
 Dr. Ernesto Santos  
 Dr. Vicente Arguelles  
 Dr. Bernardita Gabriel  
 Aurelia Gopuansuy  
 Hali Gopuansuy  
 Roberto Gopuansuy  
 Panda Devt. Corp.  
 Dr. Aurelia Leus  
 Dr. Prudencio Dy  
 Dr. Grace Luna  
 Dr. Victor Alvarez  
 Dr. Santiago del Rosario  
 Dr. Paul Tan  
 Dr. Regina Liboro  
 Dr. Salvador Valdez  
 Dr. Elizabeth Rondain  
 Dr. Manuel Kanapi  
 Dr. Antonio Mendoza  
 Dr. Genara Limson  
 Dr. Abundio Balgos  
 Dr. Gregorio Ocampo  
 Dr. Danilo Francisco  
 Crysma Trading  
 Electro Systems Ind.  
 Dr. Monina Ozaeta  
 Dr. & Mrs. Paulino  
 Tenchavez  
 Dr. Eric Nubla  
 Dr. Ma. Lourdes Gozali  
 Engr. Proceso Ramos  
 Carmelita Amora  
 Dr. Miguel Celdran  
 Jose Solano  
 Dr. Rosario Alcaneses  
 Dr. Manuel Canlas  
 Dr. Teresa Fontillas  
 Dr. Erlinda Escara  
 Dr. Dennis Garcia  
 Dr. Romeo Nuguid  
 Dr. Jorge Arkoncel  
 Dr. Luz Gamez  
 Dr. Francisco Barros  
 Dr. Rodrigo Cesario  
 Nilo's Machine  
 Herophil  
 Salvador Martinez  
 Atty. Victoria Martinez  
 Atty. Robert Abad  
 Dr. Raymund Serina  
 Alfonso Tiu/Concept  
 Packaging  
 Paris Manila Technology  
 Dr. Leticia Andres  
 Dr. Luis Capuchino  
 Dr. Julius Lecciones  
 Neil Datu  
 Arlene Pioderoda  
 Milly Chua  
 Elly Dejaresco  
 Peter Dejaresco  
 Bingo Dejaresco  
 Sister Tajanlangit  
 Danny Anastacio  
 Dr. Natividad Alimurong  
 Novartis

## Supporting the Foundation

The Foundation offers several opportunities for those who wish to support its undertakings.

### Endowments Supporting Current Projects

Endowments are invited in the following categories:

Benefactors	P 100,000.00 or more
Patrons	P 20,000.00 - P 99,000.00
Sponsors	P 10,000.00 - P 19,000.00
Donors	Less than P10,000.00
Friends of the Foundation	

Cash endowments of P 500,000.00 or more may designate their endowment to a specific research project or for the general use of the foundation.

An endowment of P 1,000,000.00 may sponsor one research project for one year.

### Endowment for the Future

Donations of money, securities, property or life insurance can be given to the Tropical Disease Foundation for general support or for specific projects designated by the donor.

### Memorial and Honorary Endowments Remembering a Loved One

Endowments may be made in honor or in memory of a friend or relative. The Foundation acknowledges this by giving a certificate of appreciation to the person honored or to the family of the deceased.



*The logo attempts to define visually the raison d'être of the Foundation using a combination of symbols:*

- *The microscope represents medical research on bacteria, viruses and parasites.*
- *The sun and the plant signify the tropics and its lush vegetation.*
- *The plant further implies the possibilities of research in the medical field.*

Tropical Disease Foundation  
C.P. Manahan Memorial Annex, Makati Medical Center  
#2 Amorsolo St., Makati City  
FAX: 810-28-74; Tel. No. 893-60-66  
Medical Plaza Makati  
Rms. 2002-2004  
FAX: 888-90-44; Tel. No. 889-04-89; 840-07-14; 840-21-78